var title_f38_37_39504="Budesonide: Patient drug information";
var content_f38_37_39504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Budesonide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/59/8116?source=see_link\">",
"       Budesonide (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/45/25303?source=see_link\">",
"       Budesonide (systemic therapy and oral inhalation): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11468 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39504=[""].join("\n");
var outline_f38_37_39504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/59/8116?source=related_link\">",
"      Budesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/45/25303?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_37_39505="Gastrointestinal manometry in amyloidosis";
var content_f38_37_39505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Gastrointestinal manometry in amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gastrointestinal manometric tracing during fasting in a 60-year-old patient with primary amyloidosis. There are low amplitude contractions at all levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Malagelada JR, Camilleri M, Stanghellini V. Manometric Diagnosis of Gastrointestinal Motility Disorders. Thieme Medical Publishers, New York 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39505=[""].join("\n");
var outline_f38_37_39505=null;
var title_f38_37_39506="PDA two D echocardiogram";
var content_f38_37_39506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiograph of patent ductus arteriosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two-dimensional echocardiographic image of the patent ductus arteriosus (arrows) was obtained by moving the transducer laterally and inferiorly from the suprasternal notch to the infraclavicular region and rotating clockwise.",
"    <div class=\"footnotes\">",
"     RA: right atrium; AAo: ascending aorta; MPA: main pulmonary artery; LA: left atrium; RPA: right pulmonary artery; LPA: left pulmonary artery; PDA: patent ductus arteriosus; DAo: descending aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39506=[""].join("\n");
var outline_f38_37_39506=null;
var title_f38_37_39507="Craniopharyngioma MRI II";
var content_f38_37_39507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Craniopharyngioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unenhanced and enhanced magnetic resonance imaging of the brain in a 55 year-old patient with decreased vision on the right due to a craniopharygioma. There is a midline, 2.2 cm, enhancing suprasellar mass bordered anteriorly by the optic chiasm, superiorly by the third ventricle, and posteriorly by the interpenduncular cistern. There is no calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence Recht, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39507=[""].join("\n");
var outline_f38_37_39507=null;
var title_f38_37_39508="E. coli asparaginase: Patient drug information";
var content_f38_37_39508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   E. coli asparaginase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/20/10567?source=see_link\">",
"     see \"E. coli asparaginase: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/1/16405?source=see_link\">",
"     see \"E. coli asparaginase: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elspar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kidrolase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. Tell your doctor about any fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, flu-like signs, sore throat, cough, or trouble breathing. Do not restart this drug if you have had an allergic reaction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701552",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to asparaginase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug caused bleeding, a blood clot, or an irritated pancreas before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatic disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever and chills while this drug is being given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures may  rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11295 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39508=[""].join("\n");
var outline_f38_37_39508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136999\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137000\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026598\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026600\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026599\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026604\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026605\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026607\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026602\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026609\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/20/10567?source=related_link\">",
"      E. coli asparaginase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/1/16405?source=related_link\">",
"      E. coli asparaginase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_37_39509="Radiologic assessment of renal disease";
var content_f38_37_39509=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiologic assessment of renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39509/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39509/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39509/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39509/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39509/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39509/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39509/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/37/39509/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of radiologic studies are used to evaluate the patient with renal disease. These tests are performed alone or in combination for the detection, diagnosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the evaluation of multiple conditions. They are principally required to assess urinary tract obstruction, kidney stones, renal cyst or mass, disorders with characteristic radiographic findings, renal vascular diseases, and vesicoureteral reflux.",
"   </p>",
"   <p>",
"    The more commonly used imaging studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plain film of the abdomen",
"     </li>",
"     <li>",
"      Ultrasonography",
"     </li>",
"     <li>",
"      Intravenous urogram",
"     </li>",
"     <li>",
"      CT scanning",
"     </li>",
"     <li>",
"      Magnetic resonance imaging",
"     </li>",
"     <li>",
"      Renal arteriography",
"     </li>",
"     <li>",
"      Renal venography",
"     </li>",
"     <li>",
"      Radionuclide scans",
"     </li>",
"     <li>",
"      Voiding cystourethrogram",
"     </li>",
"     <li>",
"      Retrograde or anterograde pyelography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of safety, ease of use, and the information provided, the most commonly used radiographic technique in patients presenting with renal disease is renal ultrasonography. Since obstruction is a readily reversible disorder,",
"    <strong>",
"     all",
"    </strong>",
"    patients presenting with renal failure of unknown etiology should undergo ultrasonography, the modality of choice to assess possible obstructive disease.",
"   </p>",
"   <p>",
"    The following is a brief introduction to the use of these techniques in the evaluation of patients with a variety of suspected or confirmed renal disorders. Detailed discussions concerning the findings and optimal use of these modalities, as well as other techniques, are also presented separately in topics reviewing individual diseases for which these modalities are routinely employed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RADIOLOGIC STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ultrasonography is the test of choice to exclude urinary tract obstruction, thereby avoiding the potential allergic and toxic complications of radiocontrast media (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77938 \" href=\"mobipreview.htm?10/0/10246\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/1\">",
"     1",
"    </a>",
"    ]. It can, in the majority of affected patients, diagnose hydronephrosis and often establish its cause. As previously mentioned, since urinary tract obstruction is easily diagnosed and reversible when treated early, ultrasonography should be performed in all patients presenting with renal failure of unknown etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although less sensitive than computed tomography in initially detecting a renal mass, ultrasonography can be useful in differentiating a simple benign cyst from a more complex cyst or a solid tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=see_link\">",
"     \"Simple and complex renal cysts in adults\"",
"    </a>",
"    .) It is also commonly used to screen for and diagnose polycystic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasonography or CT scanning should also be considered in patients with pyelonephritis who continue to have an incomplete response to antimicrobial therapy. These techniques can rule out the presence of obstruction, renal or perinephric abscesses, or other complications of pyelonephritis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62046 \" href=\"mobipreview.htm?39/31/40432\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link\">",
"     \"Acute complicated cystitis and pyelonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings on ultrasonography are also frequently utilized to assess the presence of irreversible kidney disease. Increased echogenicity is a nonspecific finding seen with many diffuse renal diseases. A treatable renal process is less likely in patients with decreased kidney size, and a high resistive index may indicate irreversible intrarenal vascular disease or arteriosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Doppler'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler renal ultrasonography can be used to evaluate renal vascular flow in multiple disorders. These include renal vein thrombosis, renal infarction and renal artery stenosis.",
"   </p>",
"   <p>",
"    Doppler is also used to obtain the resistive index, which is calculated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(Peak systolic velocity - end diastolic velocity)",
"    <br/>",
"    &nbsp; ___________________________________________",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Peak systolic velocity",
"   </p>",
"   <p>",
"    The normal resistive index is &lt;0.7. A high resistive index may indicate intrarenal vascular disease or arteriosclerosis, but may also be seen with acute tubular necrosis, obstruction to urine outflow and acute rejection of the transplanted kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scanning often provides complementary information to that obtained with ultrasonography. As an example, if the criteria for a simple cyst by ultrasonography are not satisfied, the patient should subsequently undergo CT scanning, which can distinguish (in most cases) a neoplastic lesion from a simple cyst [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=see_link\">",
"     \"Simple and complex renal cysts in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, non-contrast-enhanced helical CT scanning is the gold standard for the radiologic diagnosis of renal stone disease, including the detection of stones missed on plain films of the abdomen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69052 graphicRef72669 \" href=\"mobipreview.htm?29/11/29878\">",
"     image 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT is also used to evaluate and stage renal cell carcinoma and to diagnose renal vein thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    .) Furthermore, polycystic kidney disease can be diagnosed with CT scanning with a higher sensitivity than that obtained with renal ultrasonography, particularly in younger patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Along with renal venography and CT scanning, magnetic resonance imaging (MRI) is a gold standard for the diagnosis of renal vein thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI is also used in the evaluation of the patient with suspected or confirmed renal cell carcinoma. It may be a useful adjunct when ultrasonography and CT scanning are nondiagnostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic contrast cannot be administered due to allergy or inadequate renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=see_link\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance angiography is playing an increasing role in evaluating patients with suspected renovascular hypertension and, in many cases, has reduced the role of renal angiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the administration of gadolinium during magnetic resonance imaging has been strongly linked to an often severe disease called nephrogenic systemic fibrosis among patients with moderate to severe renal disease, particularly those requiring dialysis. As a result, it is recommended that gadolinium-based imaging be avoided, if possible, in patients with an estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    . There is no consensus among experts concerning the decision to administer gadolinium among patients with an estimated GFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Plain film of the abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain film of the abdomen is not commonly performed in patients with suspected renal disease. Among patients presenting with symptoms suggestive of nephrolithiasis, a plain film of the abdomen can identify calcium-containing, struvite, and cystine stones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62009 \" href=\"mobipreview.htm?42/7/43123\">",
"     image 4",
"    </a>",
"    ), but will miss radiolucent uric acid stones and may miss small radioopaque stones or stones overlying bony structures. As previously mentioned, the diagnostic test of choice when nephrolithiasis is suspected is the helical CT scan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intravenous urogram (pyelogram)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, the intravenous urogram (pyelogram, IVP) was the principal radiologic technique used in evaluating the patient with possible renal disease. It provides detailed information concerning caliceal anatomy and the size and shape of the kidney, and is extremely useful in detecting renal stones. However, the IVP is currently much less popular since it requires the administration of contrast and involves substantial radiation exposure, and other techniques, such as ultrasonography, frequently provide similar or more detailed information.",
"   </p>",
"   <p>",
"    Nevertheless, it can still be a valuable technique in the evaluation and diagnosis of certain structural disorders, such as medullary sponge kidney, and papillary necrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3242?source=see_link\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/21/37206?source=see_link\">",
"     \"Medullary sponge kidney\"",
"    </a>",
"    .) The IVP also has high sensitivity and specificity for the detection of stones, and provides data on the degree of obstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80493 \" href=\"mobipreview.htm?17/17/17694\">",
"     image 5",
"    </a>",
"    ). However, non-contrast-enhanced helical CT scanning is the gold standard for the radiologic diagnosis of renal stone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal arteriography is currently used less frequently because of the availability of noninvasive tests such as CT scanning and MRI. However, it remains useful in certain settings such as the patient with suspected polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/8\">",
"     8",
"    </a>",
"    ]. Arteriography is often diagnostic in this disorder, demonstrating multiple aneurysms and irregular constrictions in the larger vessels with occlusion of smaller penetrating arteries (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"mobipreview.htm?35/54/36705\">",
"     image 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A mainstay of the diagnosis of renal cell carcinoma in the past, selective renal arteriography is now rarely used except in occasional cases in which preoperative mapping of the vasculature is necessary (as when nephron sparing surgery is contemplated). On arteriography, the typical renal cell carcinoma appears to be well vascularized, has venous lakes, exhibits puddling of contrast medium in vascular spaces or necrotic areas, and shunts contrast medium rapidly into the renal vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective renal venography with inferior vena cavagram remains useful for the diagnosis of renal vein thrombosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69262 \" href=\"mobipreview.htm?7/63/8191\">",
"     image 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radionuclide studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early detection of vesicoureteral reflux and scarring is possible with radioisotope scanning with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29650?source=see_link\">",
"     technetium Tc-99m succimer",
"    </a>",
"    (DMSA) or IVP. DMSA scanning is more sensitive than the IVP in detecting renal scars and is the preferred test for many pediatric nephrologists and radiologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3242?source=see_link\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Voiding cystourethrogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding cystourethrogram, which can be performed noninvasively with a radionuclide study, can be used to detect vesicoureteral reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Retrograde or anterograde pyelography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antegrade or retrograde pyelography may be used to diagnose urinary tract obstruction. Their use for the diagnosis of obstruction has largely been supplanted by ultrasonography and CT scanning. However, they may be indicated when the history is highly suggestive (unexplained acute renal failure with a bland urine sediment in a patient with known pelvic malignancy), even though hydronephrosis may be absent (due to possible ureteral encasement) on ultrasonography and CT scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39509/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299381819\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal ultrasonography is the test of choice to exclude urinary tract obstruction, thereby avoiding the potential allergic and toxic complications of radiocontrast media (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77938 \" href=\"mobipreview.htm?10/0/10246\">",
"       image 1",
"      </a>",
"      ). Although less sensitive than computed tomography (CT) for initially detecting a renal mass, ultrasonography can also be useful in differentiating a simple benign cyst from a more complex cyst or a solid tumor, and in detecting complications of pyelonephritis in a patient who has an incomplete response to antimicrobial therapy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62046 \" href=\"mobipreview.htm?39/31/40432\">",
"       image 2",
"      </a>",
"      ). In addition, ultrasonography can identify increased echogenicity and decreased kidney size, suggesting the presence of irreversible kidney disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler renal ultrasonography can be used to evaluate renal vascular flow in multiple disorders, including renal vein thrombosis, renal infarction and renal artery stenosis. Doppler can also identify a high resistive index, which may indicate intrarenal vascular disease or arteriosclerosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Doppler'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-contrast-enhanced helical CT scanning is the gold standard for the radiologic diagnosis of renal stone disease, including the detection of stones missed on plain films of the abdomen (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69052 graphicRef72669 \" href=\"mobipreview.htm?29/11/29878\">",
"       image 3A-B",
"      </a>",
"      ). In addition, CT is also used to evaluate and stage renal cell carcinoma, and can be employed to diagnose renal vein thrombosis and polycystic kidney disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'CT scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Along with renal venography and CT scanning, magnetic resonance imaging (MRI) is a reliable test for the diagnosis of renal vein thrombosis. Magnetic resonance angiography is playing an increasing role in evaluating patients with suspected renovascular hypertension and, in many cases, has reduced the role of renal angiography. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A plain film of the abdomen is not commonly performed as the first study in patients with suspected renal disease, although it can identify calcium-containing, struvite, and cystine kidney stones of sufficient size (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62009 \" href=\"mobipreview.htm?42/7/43123\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Plain film of the abdomen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal arteriography is used less frequently because of the availability of noninvasive tests such as CT scanning and MRI. However, it remains useful in certain settings such as patients with suspected polyarteritis nodosa, since it can demonstrate aneurysms and irregular constrictions in the larger vessels with occlusion of smaller penetrating arteries (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"mobipreview.htm?35/54/36705\">",
"       image 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Renal arteriography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early detection of vesicoureteral reflux and scarring is possible with radioisotope scanning with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29650?source=see_link\">",
"       technetium Tc-99m succimer",
"      </a>",
"      (DMSA) and a voiding cystourethrogram. DMSA scanning is more sensitive than intravenous urography in detecting renal scars and is the preferred test for many pediatric nephrologists and radiologists. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radionuclide studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Voiding cystourethrogram'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/1\">",
"      Webb JA. Ultrasonography in the diagnosis of renal obstruction. BMJ 1990; 301:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/2\">",
"      Bosniak MA. The small (less than or equal to 3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies. Radiology 1991; 179:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/3\">",
"      Curry NS. Small renal masses (lesions smaller than 3 cm): imaging evaluation and management. AJR Am J Roentgenol 1995; 164:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/4\">",
"      Moghazi S, Jones E, Schroepple J, et al. Correlation of renal histopathology with sonographic findings. Kidney Int 2005; 67:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/5\">",
"      Ikee R, Kobayashi S, Hemmi N, et al. Correlation between the resistive index by Doppler ultrasound and kidney function and histology. Am J Kidney Dis 2005; 46:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/6\">",
"      Sharma AK, Rustom R, Evans A, et al. Utility of serial Doppler ultrasound scans for the diagnosis of acute rejection in renal allografts. Transpl Int 2004; 17:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/7\">",
"      Clayman RV, Surya V, Miller RP, et al. Pursuit of the renal mass. Is ultrasound enough? Am J Med 1984; 77:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/8\">",
"      Balow JE. Renal vasculitis. Kidney Int 1985; 27:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39509/abstract/9\">",
"      Dillon MJ, Goonasekera CD. Reflux nephropathy. J Am Soc Nephrol 1998; 9:2377.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7194 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39509=[""].join("\n");
var outline_f38_37_39509=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H299381819\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RADIOLOGIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Plain film of the abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intravenous urogram (pyelogram)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal venography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radionuclide studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Voiding cystourethrogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Retrograde or anterograde pyelography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H299381819\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7194|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/0/10246\" title=\"diagnostic image 1\">",
"      Ultrasound showing hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/31/40432\" title=\"diagnostic image 2\">",
"      Ultrasonography of acute pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/21/10577\" title=\"diagnostic image 3A\">",
"      CT scan showing ureteral stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/47/21233\" title=\"diagnostic image 3B\">",
"      CT scan showing large renal pelvic stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/7/43123\" title=\"diagnostic image 4\">",
"      KUB showing staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/17/17694\" title=\"diagnostic image 5\">",
"      Intravenous pyelogram showing ureteral stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/54/36705\" title=\"diagnostic image 6\">",
"      Renal arteriogram in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/63/8191\" title=\"diagnostic image 7\">",
"      Inferior vena cavagram showing renal vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9433?source=related_link\">",
"      Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=related_link\">",
"      Simple and complex renal cysts in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_37_39510="Glipizide and metformin: Drug information";
var content_f38_37_39510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glipizide and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/49/27413?source=see_link\">",
"    see \"Glipizide and metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metaglip&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients inadequately controlled on diet and exercise alone: Initial dose: Glipizide 2.5 mg/metformin 250 mg once daily with a meal. In patients with fasting plasma glucose (FPG) 280-320 mg/dL, initiate therapy with glipizide 2.5 mg/metformin 500 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Increase dose by 1 tablet/day every 2 weeks (maximum daily dose:  Glipizide 10 mg/metformin 2000 mg in divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients inadequately controlled on a sulfonylurea and/or metformin: Initial dose: Glipizide 2.5 mg/metformin 500 mg or glipizide 5 mg/metformin 500 mg twice daily with morning and evening meals; starting dose should not exceed current daily dose of glipizide (or sulfonylurea equivalent) and/or metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Increase dose in increments of no more than glipizide 5 mg/metformin 500 mg (maximum daily dose: Glipizide 20 mg/metformin 2000 mg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conservative doses are recommended in the elderly due to potentially decreased renal function;",
"     <b>",
"      do not titrate to maximum dose",
"     </b>",
"     ; should not be used in patients &ge;80 years unless renal function is verified as normal",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F176418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in the presence of renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL [males], &ge;1.4 mg/dL [females], or abnormal creatinine clearance).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F176419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in patients with impaired liver function.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: 2.5/250: Glipizide 2.5 mg and metformin hydrochloride 250 mg; 2.5/500: Glipizide 2.5 mg and metformin hydrochloride 500 mg; 5/500: Glipizide 5 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metaglip&trade; 2.5/250: Glipizide 2.5 mg and metformin hydrochloride 250 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metaglip&trade; 2.5/500: Glipizide 2.5 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metaglip&trade; 5/500: Glipizide 5 mg and metformin hydrochloride 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All doses should be administered with a meal. Twice-daily dosing should be administered with the morning and evening meals. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (noninsulin dependent, NIDDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (8% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (&lt;1% to 8%), abdominal pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Urinary tract infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (8% to 10%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glipizide, metformin, or any component of the formulation; renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females, or abnormal creatinine clearance which may also result from conditions such as cardiovascular collapse, acute myocardial infarction, and septicemia); acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Temporarily discontinue in patients undergoing radiologic studies in which intravascular iodinated contrast materials are utilized.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal, hepatic, adrenal and/or pituitary function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function and patient age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use metformin with caution in patients with congestive heart failure requiring pharmacologic management, particularly in patients with unstable or acute heart failure; risk of lactic acidosis may be increased secondary to hypoperfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid metformin use in patients with impaired liver function due to potential for lactic acidosis; use glipizide with caution in patients with severe hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed. Risk of lactic acidosis increases with age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism and increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Metformin therapy should  be temporarily discontinued prior to or at the time of  intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical procedures: Metformin therapy should be suspended for any surgical procedures (resume only after oral intake resumed and normal renal function is verified).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F176427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of GlipiZIDE. Management: Administer glipizide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the hypoglycemic effect of GlipiZIDE. Posaconazole may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F176411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies were not conducted with this combination; therefore, glipizide/metformin is classified as pregnancy category C. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glipizide: Excretion in breast milk unknown/not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin: Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F176407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause GI upset; should be taken with food to decrease GI upset. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F176405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (GlipiZIDE-MetFORMIN HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-250 mg (100): $82.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-500 mg (100): $98.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $98.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Metaglip Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-250 mg (100): $110.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia, urine (glucose and ketones), FPG, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , and fructosamine. Initial and periodic monitoring of hematologic parameters (eg, hemoglobin/hematocrit and red blood cell indices) and renal function should be performed; monitor at least annually once patient is on maintenance therapy. While megaloblastic anemia has been rarely seen with metformin, if suspected, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency should be excluded.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F176398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The combination of glipizide and metformin is used to improve glycemic control in patients with type 2 diabetes mellitus (noninsulin dependent, NIDDM) by using two different, but complementary, mechanisms of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glipizide: Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metformin: Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/37/39510/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):854-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/37/39510/abstract-text/9742977/pubmed\" id=\"9742977\" target=\"_blank\">",
"        9742977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/37/39510/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8791 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39510=[""].join("\n");
var outline_f38_37_39510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708893\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176413\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176432\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176416\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176417\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176418\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176419\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176397\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176384\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176400\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176399\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174545\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176430\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176403\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176387\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176427\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176391\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176411\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176393\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176406\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176423\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176407\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176408\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176405\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176395\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176398\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176386\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176402\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8791|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/49/27413?source=related_link\">",
"      Glipizide and metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_37_39511="Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding";
var content_f38_37_39511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39511/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39511/contributors\">",
"     Jasmohan S Bajaj, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39511/contributors\">",
"     Arun J Sanyal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39511/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39511/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39511/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/37/39511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transjugular intrahepatic portosystemic shunts (TIPS) involve creation of a low-resistance channel between the hepatic vein and the intrahepatic portion of the portal vein (usually the right branch) using angiographic techniques (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"mobipreview.htm?3/10/3239\">",
"     figure 1",
"    </a>",
"    ). The tract is kept patent by deployment of an expandable metal stent across it, thereby allowing blood to return to the systemic circulation. The ability of TIPS to function like a surgical side-to-side portacaval shunt without requiring general anesthesia and major surgery led to its rapid acceptance into clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the expanding use of TIPS has also led to its misuse in some instances.",
"   </p>",
"   <p>",
"    This topic review will discuss the role of TIPS in the management of acute esophageal, gastric, or ectopic variceal hemorrhage, and in the prevention of recurrent variceal bleeding. Other indications for the use of TIPS (eg, ascites and hydrothorax), contraindications, and complications associated with this procedure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .) A guideline (updated in 2009) issued by the American Association for the Study of Liver Diseases (AASLD) is also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/2\">",
"     2",
"    </a>",
"    ]. The AASLD guideline can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/\">",
"     www.aasld.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE VARICEAL HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several treatments are available for the management of acute variceal hemorrhage. These can be broadly grouped into treatments that address the local bleeding site and those that reduce portal pressure directly. Examples of the former are esophageal sclerotherapy, band ligation, and balloon tamponade. Treatments to reduce portal pressure include pharmacologic agents (such as somatostatin, vasopressin, and their analogues), surgically created shunts, and TIPS. In clinical practice, these modalities are sometimes used together. Patients who have recurrent bleeding or bleeding refractory to a specific therapy may benefit from one of these alternatives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the treatments available for variceal hemorrhage is optimal. This is due both to the failure of any treatment to uniformly achieve hemostasis and to the inability to arrest progression of cirrhosis or prevent liver failure. In addition, each modality has its unique spectrum of complications, which also contribute to morbidity and mortality. The choice of a specific therapeutic modality depends upon its relative efficacy and safety in a given clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Active hemorrhage from esophageal varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment of active variceal hemorrhage is to quickly arrest initial bleeding and bleeding-related complications, prevent recurrent bleeding, and minimize treatment-associated morbidity and mortality. Endoscopic and pharmacologic treatment is first-line therapy for active esophageal variceal hemorrhage. Endoscopic sclerotherapy or band ligation can be performed at the bedside by practically all trained gastroenterologists and achieves hemostasis in 80 to 90 percent of subjects. Both methods decrease early rebleeding and improve short-term survival. Pharmacologic therapy is also effective, widely available, and can be used in combination with endoscopic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have also shown that early TIPS can lead to good outcomes in select patients when performed by experienced radiologists in institutions where TIPS is readily available. Specifically, the use of early TIPS has been shown to be effective for high-risk patients, such as those with a hepatic venous pressure gradient of 20 mmHg or more or those with persistent bleeding at endoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/3\">",
"     3",
"    </a>",
"    ]. However, TIPS can be challenging in patients with active hemorrhage because it involves transporting a potentially unstable patient to the angiography suite for the procedure. In addition, it is associated with a variety of potential complications, some of which may be fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Salvage therapy for patients who are poor surgical candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 20 percent of patients fail to stop bleeding with endoscopic treatment. Other patients may rebleed in the first few days after cessation of the index bleed. A second attempt to control hemorrhage with endoscopic treatment is sometimes effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/5\">",
"     5",
"    </a>",
"    ]. However, when two attempts to control active hemorrhage fail, the risk of mortality rises exponentially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The precise definition of \"failure of endoscopic treatment\" remains controversial; we consider failure to be the recurrence of variceal hemorrhage despite at least two sessions of endoscopic treatment performed no more than two weeks apart.",
"   </p>",
"   <p>",
"    Emergency shunt surgery is extremely effective in arresting hemorrhage and preventing rebleeding, but it is associated with approximately a 50 percent mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Many patients die of liver failure and complications of surgery, despite achievement of hemostasis. Those with severe hemorrhage, tense ascites, deep coma, aspiration pneumonia, renal failure, or sepsis are at particular risk from surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple series have demonstrated the efficacy of TIPS for uncontrolled esophageal variceal hemorrhage despite emergent endoscopic and pharmacologic treatment in patients who are poor-risk candidates for urgent surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. An illustrative report focused on patients who were referred for TIPS within 72 hours of emergent endoscopic treatment and were considered to be poor-risk candidates for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients were stabilized initially with balloon tamponade and TIPS was placed semi-emergently within 12 hours. Balloon tamponade was discontinued within 12 to 24 hours after TIPS placement. TIPS was placed successfully in 29 of 30 patients and achieved hemostasis in all patients. The six-week survival was 60 percent in this cohort of moribund subjects whose expected survival rate, based upon historic controls, was about 10 percent. In those without pulmonary aspiration, the survival was 90 percent at six weeks (",
"    <a class=\"graphic graphic_figure graphicRef64881 \" href=\"mobipreview.htm?24/17/24861\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Only two episodes of early rebleeding were noted after TIPS and were due to technical problems related to stent shortening and collapse of the parenchymal tract; these were easily treated by dilation of the tract and placement of additional stents across the dilated tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Salvage therapy for patients who are good surgical candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have compared TIPS to surgery in the management of refractory hemorrhage in patients who are good surgical candidates. However, a vast body of literature exists on the use of surgery for the control of variceal hemorrhage, and underscores the fact that surgery is still a reasonable treatment option in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2009 guideline issued by the American Association for the Study of Liver Diseases concluded that TIPS or a distal splenorenal shunt were similarly effective in prevention of rebleeding in patients who failed medical therapy based upon the results of a controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Thus, it may be reasonable to consider the available expertise and the patient's individual circumstances. As an example, patients who live in remote areas and have poor access to medical services may be better served by surgical therapy. On the other hand, TIPS may be a useful temporizing measure in those awaiting liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bleeding gastric varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from gastric varices is difficult to control endoscopically, although an increasing number of endoscopic approaches have been described. Endoscopy is critical for distinguishing between an esophageal and gastric source of variceal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most settings, the initial treatment of bleeding fundic gastric varices is pharmacologic. Unfortunately, this often fails to control bleeding, necessitating the use of other modalities. The traditional treatment of patients with bleeding gastric varices that fail to respond to pharmacologic therapy has been surgical portal decompression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials have also shown that TIPS can also be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. In one study, for example, 28 patients with bleeding gastric fundal varices unresponsive to pharmacologic treatment underwent emergency TIPS. Bleeding was controlled in 96 percent, which was comparable to the success for bleeding esophageal varices (98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/12\">",
"     12",
"    </a>",
"    ]. In another series of 32 patients, hemostasis was achieved in 18 of 20 patients (90 percent) who were actively bleeding; rebleeding rates for the group as a whole were 14, 26, and 32 percent at one month, six months, and one year, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/18\">",
"     18",
"    </a>",
"    ]. Complications were observed in seven patients (22 percent), four of which were fatal.",
"   </p>",
"   <p>",
"    TIPS may be less effective than surgery in patients with bleeding gastric varices who have spontaneous splenorenal collaterals. Flow through collaterals that feed the gastric varices often persists after TIPS, and the varices do not disappear even after an adequate shunt is created [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/19\">",
"     19",
"    </a>",
"    ]. Over time, these patients remain at risk for recurrent variceal hemorrhage.",
"   </p>",
"   <p>",
"    The choice of the procedure between portal decompression and surgical ligation of the splenorenal collaterals depends upon the anatomy, underlying degree of liver failure, clinical status, and local expertise. TIPS does provide effective, although often short-term, portal decompression in this setting. Glue injection is an acceptable alternative to these strategies, although it is not currently approved for this indication in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Gastric varices'",
"    </a>",
"    .) The precise decrease in the HVPG needed to minimize the risk of rebleeding is not known, although it might be lower than for esophageal varices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/2\">",
"     2",
"    </a>",
"    ]. If spontaneous splenorenal collaterals are present, patients should be monitored closely since the effectiveness of TIPS is less predictable due to competing shunts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bleeding ectopic varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varices occasionally develop at sites other than the stomach and esophagus and come to clinical attention when they bleed. Examples are duodenal, rectal, and peristomal varices (which develop around the stoma in patients who have a colostomy). Endoscopic treatment is often unsuccessful in these cases, and traditional treatment has been surgical.",
"   </p>",
"   <p>",
"    Anecdotal reports have noted that the bleeding can also be controlled by TIPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. It is unlikely that enough cases will be seen by any center to generate \"hard data\" upon which to base therapy. One disadvantage with TIPS is that it requires close follow-up for several years. A guideline issued by the American Association for the Study of Liver Diseases recommends TIPS as the preferred approach for prevention of rebleeding in patients with ectopic varices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENT VARICEAL HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following successful treatment of variceal bleeding, several options are available for preventing recurrent bleeding. Long-term pharmacologic therapy usually with nonselective beta blockers, repeat endoscopy sessions with band ligation or sclerotherapy with the aim of obliterating esophageal varices, or a combination of the two are common strategies. However, neither of these methods alone or in combination is successful in all patients. Furthermore, endoscopic obliteration of varices requires multiple sessions with the associated risks, and recurrent hemorrhage may occur while varices are being obliterated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transjugular intrahepatic portosystemic shunt (TIPS) decompresses the portal vein, and treats the cause of variceal hemorrhage, while avoiding general anesthesia and major surgery (",
"    <a class=\"graphic graphic_figure graphicRef72311 \" href=\"mobipreview.htm?3/10/3239\">",
"     figure 1",
"    </a>",
"    ). In patients with ascites, TIPS has the added benefit of decompressing the hepatic sinusoids, thereby treating the cause of ascites. Variceal hemorrhage is unlikely to recur as long as the TIPS remains patent.",
"   </p>",
"   <p>",
"    When compared with other approaches, TIPS has many features of an optimal long-term treatment for the prevention of recurrent variceal hemorrhage. Several clinical trials have now been performed to see if these considerations hold true in practice. Interpretation of these data suggests that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TIPS is more effective than endoscopic treatment for the prevention of recurrent bleeding.",
"     </li>",
"     <li>",
"      Compared with endoscopic methods, TIPS does not improve mortality and may be associated with increased mortality in those with advanced liver failure.",
"     </li>",
"     <li>",
"      TIPS is associated with its unique profile of complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TIPS versus endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical trials have evaluated the efficacy of TIPS versus endoscopic therapy for the prevention of recurrent variceal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/24-30\">",
"     24-30",
"    </a>",
"    ]. Most used endoscopic sclerotherapy, but there have also been studies comparing TIPS to endoscopic band ligation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/20,28,31-33\">",
"     20,28,31-33",
"    </a>",
"    ]. Comparison among these trials can be difficult for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Different sclerotherapy protocols were used.",
"     </li>",
"     <li>",
"      The severity of liver failure varied.",
"     </li>",
"     <li>",
"      While most studies randomized patients within 24 hours of admission, one trial, which found no benefit of TIPS, focused primarily on long-term rebleeding and randomized patients after a mean of 10 days compared to one to two days in the other reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/24\">",
"       24",
"      </a>",
"      ]. The timing issue may be important since it has been suggested that TIPS is significantly better than sclerotherapy in preventing rebleeding only when it is performed less than one week after the initial bleed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All but one study demonstrated a significant decrease in the risk of rebleeding in patients undergoing TIPS (",
"    <a class=\"graphic graphic_figure graphicRef52679 \" href=\"mobipreview.htm?16/2/16430\">",
"     figure 3",
"    </a>",
"    ). The differences across studies were due to the variable rebleeding rates after endoscopic treatment rather than after TIPS (which was approximately 20 percent). Despite the beneficial effects on bleeding, TIPS was associated with either no survival advantage or poorer survival. In addition, hepatic encephalopathy occurred at least twice as frequently following TIPS in most of the studies. Advanced age, liver failure, shunt fraction (shunt diameter), and a history of encephalopathy prior to TIPS are all risk factors for worsening encephalopathy after TIPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the superiority of TIPS for prevention of rebleeding may be offset by its failure to improve survival and by increasing morbidity due to the development of liver failure and encephalopathy.",
"   </p>",
"   <p>",
"    Additional studies continue to evaluate strategies involving TIPS for prevention of rebleeding:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One such report found that performance of TIPS within 24 hours of endoscopic therapy in patients with a hepatic pressure venous gradient &gt;20 mmHg was significantly more effective than continued endoscopic therapy in preventing rebleeding and improving in-hospital and one-year mortality rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study examined outcomes in patients who had been part of a randomized trial comparing TIPS with medical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/36\">",
"       36",
"      </a>",
"      ]. The patients in the trial either had ongoing bleeding despite endoscopic therapy or were at high risk of rebleeding. TIPS was preformed within 72 hours of the initial endoscopy in 45 patients with variceal bleeding (62 percent were done within 24 hours), whereas 30 were treated medically. At one year, patients treated with TIPS were less likely to have failure to control bleeding or rebleeding than those treated medically (7 versus 47 percent). In addition, patients who underwent TIPS had higher one-year actuarial probability of survival (86 versus 70 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More studies are needed to validate these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recurrence of portal hypertension and stent stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal cause of rebleeding after TIPS is the recurrence of portal hypertension (",
"    <a class=\"graphic graphic_table graphicRef53289 \" href=\"mobipreview.htm?7/45/7899\">",
"     table 1",
"    </a>",
"    ). This may result from TIPS thrombosis, stent retraction and kinking, stent stenosis, or the development of right heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TIPS thrombosis usually occurs within the first month and is more likely to occur in moribund individuals. Its development has been associated with the presence of a biliary-TIPS fistula. It has been proposed that systemic anticoagulation can prevent TIPS thrombosis, but this carries the risks of inducing hemorrhage; anticoagulation is rarely routinely used in North America.",
"     </li>",
"     <li>",
"      Stent retraction into the parenchyma tissue tract and stent kinking can be avoided by careful attention to technique.",
"     </li>",
"     <li>",
"      Stent stenosis is the most common cause of recurrent portal hypertension. It is due to the ingrowth of tissue from the surrounding liver into the stent lumen eventually occluding it [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Virtually all long-term survivors after TIPS experience TIPS stenosis within the first two years, necessitating surveillance by either Doppler sonography or angiography, although the rates have considerably diminished with the use of covered stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/19,37-39\">",
"     19,37-39",
"    </a>",
"    ]. Doppler sonography is specific but somewhat insensitive depending upon the specific cutoffs used for the diagnosis of stent stenosis. Angiography is the gold standard for the detection of stent stenosis and is required for its treatment. A commonly used regimen is angiography at 6 and 12 months after TIPS and annually thereafter for the first three years. The propensity for development of stent stenosis decreases after four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39511/abstract/19\">",
"     19",
"    </a>",
"    ]. Newer coated stents show promise for reducing the incidence of stent stenosis with high patency rates seen in several randomized and retrospective trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/9/12434?source=see_link\">",
"       \"Patient information: Screening for esophageal varices (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that transjugular intrahepatic portosystemic shunt (TIPS) be used primarily as a salvage therapy in patients with recurrent variceal bleeding despite an adequate trial of endoscopic and pharmacologic treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). There is emerging evidence suggesting a role for early TIPS in the treatment of selected patients with active variceal hemorrhage. Shunt surgery can also be considered in this setting in centers with expertise in these procedures. TIPS is preferred to shunt surgery in patients with poor liver function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute variceal hemorrhage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevention of recurrent variceal hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest TIPS in patients with bleeding gastric varices despite pharmacologic treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Endoscopic therapy with glue injection is an acceptable alternative in settings where it is available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=see_link&amp;anchor=H27#H27\">",
"       \"Treatment of active variceal hemorrhage\", section on 'Gastric varices'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest TIPS in patients with bleeding ectopic varices (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Endoscopic and surgical approaches may be acceptable alternatives where expertise is available. Endoscopic approaches tend to be unsuccessful for long-term prevention. Surgical approaches should be considered based upon the availability of local expertise and should generally be performed in patients with relatively preserved liver function.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/1\">",
"      Grace ND. The side-to-side portacaval shunt revisited. N Engl J Med 1994; 330:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/2\">",
"      Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010; 51:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/3\">",
"      Monescillo A, Mart&iacute;nez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/4\">",
"      Freedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics 1993; 13:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/5\">",
"      Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997; 92:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/6\">",
"      Villeneuve JP, Pomier-Layrargues G, Duguay L, et al. Emergency portacaval shunt for variceal hemorrhage. A prospective study. Ann Surg 1987; 206:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/7\">",
"      Stein C, Korula J. Variceal bleeding. What are the treatment options? Postgrad Med 1995; 98:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/8\">",
"      Rikkers LF, Jin G, Burnett DA, et al. Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. Am J Surg 1993; 165:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/9\">",
"      Orloff MJ, Bell RH Jr, Hyde PV, Skivolocki WP. Long-term results of emergency portacaval shunt for bleeding esophageal varices in unselected patients with alcoholic cirrhosis. Ann Surg 1980; 192:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/10\">",
"      Rikkers LF, Jin G. Emergency shunt. Role in the present management of variceal bleeding. Arch Surg 1995; 130:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/11\">",
"      Jalan R, John TG, Redhead DN, et al. A comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage. Am J Gastroenterol 1995; 90:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/12\">",
"      Chau TN, Patch D, Chan YW, et al. \"Salvage\" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998; 114:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/13\">",
"      Sahagun G, Benner KG, Saxon R, et al. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage. Am J Gastroenterol 1997; 92:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/14\">",
"      LaBerge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995; 108:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/15\">",
"      Ba&ntilde;ares R, Casado M, Rodr&iacute;guez-L&aacute;iz JM, et al. Urgent transjugular intrahepatic portosystemic shunt for control of acute variceal bleeding. Am J Gastroenterol 1998; 93:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/16\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996; 111:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/17\">",
"      Henderson JM, Boyer TD, Kutner MH, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006; 130:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/18\">",
"      Barange K, P&eacute;ron JM, Imani K, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology 1999; 30:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/19\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/20\">",
"      Lo GH, Liang HL, Chen WC, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007; 39:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/21\">",
"      Bernstein D, Yrizarry J, Reddy KR, et al. Transjugular intrahepatic portosystemic shunt in the treatment of intermittently bleeding stomal varices. Am J Gastroenterol 1996; 91:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/22\">",
"      Allgaier HP, Ochs A, Haag K, et al. [Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent-shunt (TIPS)]. Dtsch Med Wochenschr 1995; 120:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/23\">",
"      Sort P, Elizalde I, Llach I, et al. Duodenal variceal bleeding treated with a transjugular intrahepatic portosystemic shunt. Endoscopy 1995; 27:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/24\">",
"      Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/25\">",
"      Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997; 126:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/26\">",
"      Cabrera J, Maynar M, Granados R, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/27\">",
"      R&ouml;ssle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/28\">",
"      Jalan R, Forrest EH, Stanley AJ, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997; 26:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/29\">",
"      Merli M, Salerno F, Riggio O, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology 1998; 27:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/30\">",
"      Sauer P, Theilmann L, Stremmel W, et al. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997; 113:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/31\">",
"      Pomier-Layrargues G, Villeneuve JP, Desch&ecirc;nes M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut 2001; 48:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/32\">",
"      G&uuml;lberg V, Schepke M, Geigenberger G, et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol 2002; 37:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/33\">",
"      Sauer P, Hansmann J, Richter GM, et al. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy 2002; 34:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/34\">",
"      Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/35\">",
"      Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis 1996; 16:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/36\">",
"      Garcia-Pag&aacute;n JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013; 58:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/37\">",
"      Charon JP, Alaeddin FH, Pimpalwar SA, et al. Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 2004; 15:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/38\">",
"      Maleux G, Nevens F, Wilmer A, et al. Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures. Eur Radiol 2004; 14:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39511/abstract/39\">",
"      Bureau C, Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27:742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1265 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39511=[""].join("\n");
var outline_f38_37_39511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE VARICEAL HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Active hemorrhage from esophageal varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Salvage therapy for patients who are poor surgical candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Salvage therapy for patients who are good surgical candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bleeding gastric varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bleeding ectopic varices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION OF RECURRENT VARICEAL HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TIPS versus endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recurrence of portal hypertension and stent stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1265\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1265|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/10/3239\" title=\"figure 1\">",
"      Transjugular intrahepatic portosystemic shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/17/24861\" title=\"figure 2\">",
"      TIPS high risk varic bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/2/16430\" title=\"figure 3\">",
"      EST v TIPS variceal rebleed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1265|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7899\" title=\"table 1\">",
"      GI bleeding after TIPS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15448?source=related_link\">",
"      Complications of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/9/12434?source=related_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_37_39512="Superior mesenteric arterty angioplasty and stent";
var content_f38_37_39512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Superior mesenteric arterty angioplasty and stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arteriogram (A) shows filling of the jejunal, ileal, ileocolic, right colic, and middle colic arteries. There is a small amount of retrograde filling of the celiac axis via the pancreaticoduodenal arcade. The stenosis of the SMA is not visible on this view. A steep right anterior oblique view of the SMA (B) shows a short segment stenosis of the proximal SMA at its origin (thick white arrow). A stent has been positioned in the proximal SMA (C) in the region of the stenosis (thin white arrow) and expanded using a balloon. A selective SMA arteriogram (D) post-angioplasty shows significant improvement in the severity of the stenosis following stent placement (white arrowhead).&nbsp;",
"    <div class=\"footnotes\">",
"     SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39512=[""].join("\n");
var outline_f38_37_39512=null;
var title_f38_37_39513="New therapies for angina pectoris";
var content_f38_37_39513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   New therapies for angina pectoris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39513/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39513/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39513/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39513/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39513/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39513/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/37/39513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the increasing success of conventional medical therapies and the continued development and improvement of percutaneous coronary intervention (PCI), a significant number of patients with ischemic heart disease and angina pectoris cannot be successfully managed.",
"   </p>",
"   <p>",
"    Many of these patients are not candidates for revascularization by PCI or coronary artery bypass graft surgery (CABG) because of one or more of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unsuitable anatomy, such as diffuse coronary disease",
"     </li>",
"     <li>",
"      One or several prior PCIs or CABGs, which may limit further benefit or preclude further revascularization",
"     </li>",
"     <li>",
"      Lack of vascular conduits for CABG",
"     </li>",
"     <li>",
"      Severely impaired left ventricular function in patients with previous CABG or PCI",
"     </li>",
"     <li>",
"      Concurrent diseases that increase perioperative or postoperative morbidity or mortality (eg, cerebrovascular disease, advanced complications of diabetes, chronic kidney disease)",
"     </li>",
"     <li>",
"      Age, often in combination with other factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a substantial proportion of patients undergoing PCI or CABG do not achieve complete revascularization. Many of these patients continue to experience residual anginal symptoms or myocardial ischemia despite maximal medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The newer medical and mechanical therapies that are currently being evaluated for treating patients with refractory angina will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medical therapies are being evaluated for the treatment of refractory angina. Only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    has been approved for use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ranolazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     Ranolazine",
"    </a>",
"    was approved by the United States FDA in 2006 for management of chronic stable angina. Although initially thought to act by partial inhibition of fatty acid oxidation, it was later realized that ranolazine had that effect only at serum levels not achieved with the usual dosing.",
"   </p>",
"   <p>",
"    A more important mechanism for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    may be the prevention of both calcium overload and the subsequent increase in diastolic tension due to inhibition of late inward sodium channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Since this sodium channel frequently fails to inactivate in a number of important myocardial disease states such as ischemia and hypertrophy, excess entry of sodium ions leads to activation of the",
"    <span class=\"nowrap\">",
"     sodium/calcium",
"    </span>",
"    exchanger, thereby raising calcium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/6\">",
"     6",
"    </a>",
"    ]. Given the normal rapid inaction of the late inward sodium channel in normal myocytes, the drug does not exert a significant effect on the normal myocardium at usual dosages. This potentially increases its therapeutic window.",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    is 500 mg twice daily. For patients who remain symptomatic, 1000 mg twice daily may be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue from the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    for symptom control is whether it might improve cardiovascular outcomes. The lack of such benefit was demonstrated in the MERLIN-TIMI 36 trial in which over 6000 patients with an acute coronary syndrome were randomly assigned to placebo or to ranolazine (initiated intravenously and followed by oral therapy of extended release 1000 mg twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/7\">",
"     7",
"    </a>",
"    ]. At one year, there was no significant difference between the two groups in the primary composite, efficacy end point of cardiovascular death, MI, or recurrent ischemia or any of the safety end points including total mortality or symptomatic documented arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Stable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    in patients with chronic stable angina has been demonstrated in several randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the MARISA trial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"       ranolazine",
"      </a>",
"      monotherapy resulted in a dose-dependent increase in pain-free exercise duration and time to angina in 191 patients, with a 1000 mg twice daily dose being more effective than a lower dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the CARISA trial, 823 patients receiving background antianginal therapy (calcium channel blocker or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ) were randomly assigned to placebo or one of two doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"       ranolazine",
"      </a>",
"      (750 or 1000 mg twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/8\">",
"       8",
"      </a>",
"      ]. After 12 weeks of therapy, both doses of ranolazine significantly increased symptom-limited exercise duration, time to onset of angina, and (at peak ranolazine blood level) time to ST segment depression, and reduced angina frequency by 0.8 and 1.2 episodes per week, compared to placebo.",
"     </li>",
"     <li>",
"      In the ERICA trial, 565 stable patients with more than three anginal attacks per week were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"       ranolazine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/9\">",
"       9",
"      </a>",
"      ]. All patients were taking 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      per day and were allowed to be on long-acting nitrates but not beta blockers; the patients had 5.63 episodes of angina per week at baseline. Ranolazine significantly improved the primary end point of anginal episodes per week compared to placebo (2.88 versus 3.31).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Unstable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;A different population was studied in the MERLIN-TIMI 36 trial cited above of patients with an acute coronary syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. In the subset of 3565 patients who had prior chronic angina,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    significantly reduced the primary end point of cardiovascular death, MI, and recurrent ischemia due entirely to a significant reduction in recurrent ischemia (HR 0.78, 95% CI 0.67-0.91) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/11\">",
"     11",
"    </a>",
"    ]. There was also an almost significant trend toward a lower rate of worsening angina (HR 0.77, 95% CI 0.55-1.00) and a significant improvement in exercise duration on a treadmill (514 versus 482 seconds).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antiarrhythmic effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     Ranolazine",
"    </a>",
"    has not been evaluated as a primary anti-arrhythmic agent, although it has exhibited a favorable anti-arrhythmic profile in the MERLIN-TIMI36 Trial (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Glycometabolic effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    in the MERLIN-TIMI-36 trial population resulted in a statistically significant 0.3 percent absolute reduction in HbA1c levels that was even more pronounced in patients with diabetes mellitus. There may also have been a reduction in progression to overt clinical diabetes as defined by increase in fasting blood sugar above 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1",
"    <span class=\"nowrap\">",
"     mmol/liter)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/12\">",
"     12",
"    </a>",
"    ]. The mechanism of this effect is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    produces a dose-dependent increase in the QT interval, the FDA recommended that it should be reserved for patients who have not had an adequate response with other antianginal drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/13\">",
"     13",
"    </a>",
"    ]. We would be more restrictive, limiting the use of ranolazine to patients who have failed all other antianginal therapies. Ranolazine is contraindicated in patients with preexisting QT interval prolongation or hepatic disease, and in patients taking other drugs that prolong the QT interval or that are potent or moderately potent inhibitors of CYP3A4, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    . Ranolazine also inhibits pathways involved in the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , and dose reduction may be required.",
"   </p>",
"   <p>",
"    Like other drugs that prolong the QT interval,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    inhibits the HERG channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, the effect is generally less than with other drugs (mean QTc prolongation 2.4 ms in a review of 746 patients treated for almost three years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/16\">",
"     16",
"    </a>",
"    ] and torsade de pointes has not yet been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. Most drugs that cause torsade de pointes show reverse use dependence, which is defined as the inverse correlation between the heart rate and QT interval. The apparent lack of reverse use dependence with ranolazine may protect against the development of torsade de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H3#H3\">",
"     \"Acquired long QT syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the largest reported long-term (greater than one year) experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    (746 patients treated for almost three years), 10 percent discontinued therapy due to adverse events attributed to ranolazine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/16\">",
"     16",
"    </a>",
"    ]. Only advanced age (&gt;64 years) was predictive of the need to withdraw the drug. The annual mortality rate was 3.0 percent and did not exceed predicted rates.",
"   </p>",
"   <p>",
"    In the MERLIN-TIMI 36 trial treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    was associated with a 3 percent lower frequency of VT, a 10.3 percent lower incidence of supraventricular tachycardia, and a 0.7 percent reduction in the onset of new atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a history of chronic stable angina, including those who are stable after an acute coronary syndrome,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    is effective at reducing anginal symptoms and improving exercise capacity, when added to standard antianginal therapy. It may also be an effective anti-arrhythmic agent, although that aspect of its activity needs more extensive clinical testing.",
"   </p>",
"   <p>",
"    We agree with the following weak recommendation which was made in 2012 guideline on the diagnosis and management of stable ischemic heart disease from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Physicians/American",
"    </span>",
"    Association for Thoracic",
"    <span class=\"nowrap\">",
"     Surgery/Preventive",
"    </span>",
"    Cardiovascular Nurses",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and",
"    <span class=\"nowrap\">",
"     Interventions/Society",
"    </span>",
"    of Thoracic Surgeons",
"    <span class=\"nowrap\">",
"     (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"       Ranolazine",
"      </a>",
"      can be a substitute for beta blockers for relief of anginal symptoms if initial treatment with beta blockers leads to unacceptable side effects or is ineffective or is contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     Ranolazine",
"    </a>",
"    can be combined with beta blockers for relief of symptoms if initial monotherapy with beta blockers is unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inhibition of fatty acid oxidation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of fatty acid oxidation represents a different approach to the management of angina. Switching from fatty acid oxidation to glucose oxidation increases cardiac metabolic efficiency. Three such agents are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    , trimetazidine, and perhexiline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, ranolazine is discussed separately above because inhibition of fatty acid oxidation may not be its primary mode of action.",
"   </p>",
"   <p>",
"    Although the heart uses both glucose and fatty acids as fuel, during periods of stress the heart uses more fatty acids, which is less oxygen efficient. Inhibition of fatty acid oxidation shifts the equilibrium toward increased use of glucose, improving the efficient use of oxygen.",
"   </p>",
"   <p>",
"    A potential advantage of these drugs is that, in contrast to nitrates, they may be safe in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    or other phosphodiesterase type 5 inhibitor for erectile dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=see_link&amp;anchor=H20#H20\">",
"     \"Sexual activity in patients with heart disease\", section on 'Adverse interaction with nitrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Trimetazidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of trimetazidine was evaluated in the TRIMPOL II trial in which 426 patients with stable, effort-induced angina who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    were randomly assigned to trimetazidine (20 mg three times daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/24\">",
"     24",
"    </a>",
"    ]. At 12 weeks, trimetazidine therapy was associated with greater improvements during exercise in time to 1 mm ST segment depression, time to onset of angina, total workload, and the mean weekly number of anginal episodes.",
"   </p>",
"   <p>",
"    A meta-analysis from the Cochrane database included 23 studies of 1378 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared to placebo, trimetazidine was associated with the following significant benefits: a reduction in weekly angina episodes (mean 1.44); and improved exercise time to 1 mm ST segment depression. Among four small trials that compared trimetazidine to other antianginal drugs, one favored trimetazidine over nitrates and three tended to favor other drugs. Trimetazidine may result in fewer dropouts due to adverse effects. The authors concluded that large, long-term trials were required to assess the clinical role of trimetazidine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Perhexiline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antianginal efficacy of perhexiline was demonstrated in older trials, even in patients not controlled with other antianginal drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/21,22,26,27\">",
"     21,22,26,27",
"    </a>",
"    ]. However, its use markedly declined in the early 1980s after reports of hepatotoxicity and peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/22\">",
"     22",
"    </a>",
"    ]. These complications most often occur in patients who are slow hydroxylators and their incidence can be dramatically reduced by maintaining plasma drug concentrations between 150 and 600",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]. These findings led to increased use in some areas, such as Australia and Europe, in patients with refractory angina who are not candidates for or refuse revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nicorandil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicorandil, a potassium channel activator, is used for the treatment of angina in a number of countries. It has multiple actions that are beneficial in coronary artery disease. It is an arterial and venous dilator and improves coronary blood flow due to potassium channel opening and nitrate effect. Since ATP dependent potassium channels play a role in ischemic preconditioning, nicorandil may also mimic a natural process of ischemic preconditioning, protecting the heart from subsequent ischemic attacks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of nicorandil (20 mg twice per day) on coronary events was evaluated in the IONA trial of 5126 patients with chronic stable angina who were receiving other standard therapies (antiplatelet drugs, beta blockers, calcium channel blockers, statins, and ACE inhibitors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/28\">",
"     28",
"    </a>",
"    ]. After a mean follow-up of 1.6 years, nicorandil reduced the primary end point (coronary death, nonfatal MI, or unplanned hospitalization for angina) by 17 percent (13 versus 15.5 for placebo, hazard ratio 0.83, 95% CI 0.72-0.97). There was an almost significant reduction in the secondary end point of death and nonfatal MI (4.2 versus 5.2 percent) and significant reductions in the incidence of an acute coronary syndrome (6 versus 7.6 percent) and all cardiovascular events (14.7 versus 17 percent).",
"   </p>",
"   <p>",
"    IONA was an outcome study and provided little information regarding the effects of nicorandil on symptoms of angina. Worsening of anginal status was not significantly different in patients taking nicorandil compared to those on placebo (22 versus 24 percent, respectively).",
"   </p>",
"   <p>",
"    Nicorandil is available in Europe and elsewhere for the treatment of angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271903048\">",
"    <span class=\"h2\">",
"     Allopurinol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    , a xanthine oxidase inhibitor used in the prevention of recurrent gout, has been shown to decrease myocardial oxygen demand per unit of cardiac output in patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/44/27337?source=see_link&amp;anchor=H11#H11\">",
"     \"Role of oxidative stress in heart failure\", section on 'Allopurinol'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     \"Allopurinol: Drug information\"",
"    </a>",
"    .) The potential use of allopurinol as an antianginal agent, when added to standard therapy, was evaluated in a crossover study which randomly assigned 65 patients with documented coronary artery disease to either allopurinol 600 mg per day or placebo for six weeks before crossover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/29\">",
"     29",
"    </a>",
"    ]. Allopurinol, compared to placebo, significantly increased the median time to ST depression (298 versus 249 seconds respectively from a baseline of 232 seconds) and median total exercise time (393 versus 307 seconds respectively from a baseline of 301 seconds). Further evaluation of allopurinol is necessary before it can be recommended as an antianginal agent.",
"   </p>",
"   <p>",
"    The mechanism of the anti-ischemic effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    was evaluated in a study of 80 patients with stable CAD on optimal medical therapy who were randomly assigned to either allopurinol (600",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/30\">",
"     30",
"    </a>",
"    ]. The drug significantly improved measures of endothelium-dependent vasodilation and completely abolished oxidative stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endothelin receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin (ET)-1, which is produced by the vascular endothelium, modulates vascular tone via two receptors (ET-A and ET-B). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/20/11592?source=see_link\">",
"     \"Role of endothelin in heart failure\"",
"    </a>",
"    .) Endogenous endothelin causes vasoconstriction in epicardial coronary arteries in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These findings suggest a possible role for endothelin antagonists, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    , in the treatment of angina.",
"   </p>",
"   <p>",
"    However, no clinical trials to date have examined the role of endothelin receptor blockers for reducing anginal symptoms. Furthermore, selective ET-A receptor blockade may have an adverse effect. This possibility was illustrated in a report of 30 patients undergoing PCI which found that, compared to intracoronary saline, an intracoronary injection of a selective ET-A receptor blocker prevented the normal reduction in myocardial ischemia on repeat balloon inflations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/33\">",
"     33",
"    </a>",
"    ]. This may be due to a \"steal effect\" on collateral blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ivabradine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ivabradine inhibits a specific sinus node pacemaker current, thereby lowering the heart rate. In a double-blind, placebo-controlled trial, ivabradine therapy was associated with an increase in the exercise time to 1 mm ST segment depression and limiting angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/34\">",
"     34",
"    </a>",
"    ]. Randomized withdrawal in these patients led to deterioration in all exercise parameters, but there was no evidence of rebound as can be seen with beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1827?source=see_link\">",
"     \"Withdrawal syndromes with antihypertensive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a subsequent double-blind trial comparing ivabradine to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    in 939 patients with stable angina, the clinical improvements were similar with the two drugs, including a reduction in the number of anginal episodes by about two-thirds and increases in total exercise duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of whether ivabradine, when added to beta blocker therapy in patients with stable angina, improves exercise capacity was addressed in a study of 889 patients receiving 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients were randomly assigned to ivabradine 5 mg twice daily for two months (and then increased to 7.5 mg twice daily for an additional two months) or placebo. At four months ivabradine significantly improved total exercise duration by 24.3 compared to 7.7 seconds.",
"   </p>",
"   <p>",
"    The efficacy of ivabradine at improving a composite endpoint of cardiovascular death, myocardial infarction, and hospitalization for heart failure was evaluated in a trial of over 10,000 patients with stable coronary artery disease and left ventricular systolic dysfunction (left ventricular ejection fraction &lt;40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/37\">",
"     37",
"    </a>",
"    ].There was no significant difference between ivabradine and placebo at a median follow up of 19 months. In a prespecified subgroup of patients with heart rate of 70 beats per minute or greater, ivabradine treatment did not affect the primary composite outcome. However, it did significantly reduce the secondary endpoints of admission to hospital for fatal and non-fatal myocardial infarction and coronary revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fasudil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observational studies suggested that fasudil, an inhibitor of Rho kinase which is involved in the vascular smooth muscle contractile response, is of benefit in patients with stable and microvascular angina (ie, angina with normal coronary arteries) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter, placebo-controlled trial, 84 patients with stable angina and reproducible exercise times were randomly assigned to fasudil (titrated to a dose of 80 mg twice daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/39\">",
"     39",
"    </a>",
"    ]. Fasudil therapy produced a significantly greater time to &ge;1 mm ST segment depression at both peak (172 versus 44 s with placebo) and trough (93 versus 24 s) but no difference in time to angina, frequency of angina or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    use, or Canadian Cardiovascular Society (CCS) functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that testosterone improves endothelial dysfunction and may be an effective antianginal agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .) This was addressed in a trial of 46 men with stable angina pectoris who were randomly assigned to placebo or a daily low dose (5 mg) transdermal testosterone patch for 12 weeks, in addition to other antianginal medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/41\">",
"     41",
"    </a>",
"    ]. Testosterone significantly increased the time to 1 mm ST segment depression on treadmill exercise testing compared to placebo (309 versus 361 s at 12 weeks).",
"   </p>",
"   <p>",
"    Given the potential for side effects, further trials are warranted before testosterone can be considered as a therapy for angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stem cell therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation of hematopoietic or bone marrow mesenchymal stem cells has been evaluated as a therapeutic option in patients after myocardial infarction or with ischemic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18617?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetic and cellular therapy in heart failure and myocardial infarction\", section on 'Cellular cardiomyoplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefit of intramyocardial bone marrow cell injection was studied in 50 patients with chronic angina refractory to standard medical therapy who were randomly assigned to an intramyocardial injection of either autologous bone marrow-derived mononuclear cells or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/42\">",
"     42",
"    </a>",
"    ]. After three month follow-up, active therapy was associated with a statistically significant, but modest, improvement in myocardial perfusion compared with placebo as well as improvement in the Canadian Cardiovascular Society Angina score (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). Further investigation is necessary to evaluate not only efficacy but also safety concerns.",
"   </p>",
"   <p>",
"    It should be noted that other studies of intramyocardial cell injections have produced different results and that at the present time there is no scientific rationale for this therapy or any plausible mechanism of action that could explain such a result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Therapeutic angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data evaluating the possible role of therapeutic angiogenesis for refractory angina are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/4/6216?source=see_link\">",
"     \"Therapeutic angiogenesis for management of refractory angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715362305\">",
"    <span class=\"h2\">",
"     High-dose statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin therapy in appropriately-selected patients can reduce mortality and the incidence of acute coronary syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H50#H50\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Lipid lowering versus coronary intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, there is increasing evidence that high-dose therapy reduces the incidence of anginal episodes in patients with stable ischemic heart disease. Two trials, AVERT and DUAAL, compared high-dose statin therapy to nonstatin-containing antianginal regimens. The applicability of these trials to current practice is unclear since statin therapy is recommended in virtually all patients with ischemic heart disease. Nevertheless, they are compatible with an antianginal effect of statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the AVERT trial, 80 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    daily led to a reduction in the rate of hospitalization for worsening angina compared to patients treated with angioplasty but not statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/43\">",
"     43",
"    </a>",
"    ]. In the DUAAL trial, 311 patients with stable ischemic heart disease, who were on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other antianginal therapy, were randomly assigned to one of three treatment arms:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    atorvastatin 80",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    or amlodipine 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    plus atorvastatin 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/44\">",
"     44",
"    </a>",
"    ]. The primary efficacy endpoint, the number of ischemic episodes during 48 hour ambulatory electrocardiographic monitoring, decreased significantly from baseline (&gt;66 percent) in all three groups. There was no significant difference in outcome among the three groups, with more than 50 percent of patients becoming free of episodes of transient myocardial ischemia at 26 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MECHANICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three mechanical therapies (enhanced external counterpulsation, spinal cord stimulation, and transmyocardial laser revascularization) have been evaluated for the treatment of angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Enhanced external counterpulsation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced external counterpulsation (EECP) is a technique that increases arterial blood pressure and retrograde aortic blood flow during diastole (diastolic augmentation). Cuffs are wrapped around the patients legs and, using compressed air, sequential pressure (300 mmHg) is applied (from the lower legs to lower and upper thighs) in early diastole to propel blood back to the heart.",
"   </p>",
"   <p>",
"    The role of EECP was evaluated in the MUST-EECP trial, which randomly assigned 139 outpatients with angina, documented coronary artery disease, and a positive exercise tolerance test to 35 hours of active EECP using a cuff pressure of 300 mmHg or inactive counterpulsation using a cuff pressure of 75 mmHg over a four to seven week period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/45\">",
"     45",
"    </a>",
"    ]. The following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active EECP was well tolerated without limiting side effects.",
"     </li>",
"     <li>",
"      Exercise duration increased to a similar degree in both the active and inactive EECP groups; there was also no significant difference in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      use.",
"     </li>",
"     <li>",
"      Patients undergoing active EECP had a significant increase in time to &ge;1 mm ST segment depression compared to baseline (379 versus 337 seconds), while there was no change in the inactive group.",
"     </li>",
"     <li>",
"      More patients undergoing active EECP had a decrease in anginal episodes and fewer had an increase in angina compared to the inactive group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted in multicenter registries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In a series of 363 patients, 72 percent improved from severe to no or mild angina and 52 percent discontinued the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/47\">",
"     47",
"    </a>",
"    ]. At two years, the decrease in angina persisted in 55 percent of patients, survival was 83 percent, and major adverse cardiac event-free survival was 70 percent. Repeat EECP was required in 20 percent.",
"   </p>",
"   <p>",
"    The mechanism of these benefits is not clear, but is probably related, at least in part, to improvements in stress-induced myocardial perfusion, left ventricular diastolic filling, peripheral arterial flow-mediated dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/48\">",
"     48",
"    </a>",
"    ], and endothelial function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/48-53\">",
"     48-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on chronic stable angina concluded that more clinical trial data are required before EECP can be recommended and this conclusion was not changed in the 2007 focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. EECP has met with only limited acceptance in practice.",
"   </p>",
"   <p>",
"    The Centers of Medicare and Medicaid Services (CMS) in the United States has approved payment for EECP in patients with Canadian Cardiovascular Society class III or IV angina (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) who, in the opinion of a cardiologist or cardiovascular surgeon, are not readily amenable to percutaneous coronary intervention or coronary artery bypass graft surgery because the patient is inoperable or at high risk for complications, or the coronary anatomy is not suitable for revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Spinal cord stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord stimulation at the T1 to T2 level is another approach to the management of refractory angina. This technique may have beneficial effects on angina by suppressing the capacity of intrinsic cardiac neurons to generate activity during myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/57\">",
"     57",
"    </a>",
"    ]; alternatively, it may provide benefit by reducing sympathetic activity or by redistributing myocardial blood flow from nonischemic to ischemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique is safe, has antiischemic effects, improves NYHA functional class, reduces hospital admissions, and increases quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In contrast to beta blockers, which are also sympatholytic, withholding spinal cord stimulation does not result in an adverse clinical rebound phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest trial (ESBY), 104 patients at high risk for surgery were randomly assigned to CABG or spinal cord stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/62\">",
"     62",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both techniques reduced angina and the use of nitrates to a similar extent.",
"     </li>",
"     <li>",
"      The CABG group had a greater increase in exercise capacity, less ST-segment depression at maximum and comparable workloads, and an increase in the rate-pressure product both at maximum and comparable workloads compared to the group receiving spinal cord stimulation.",
"     </li>",
"     <li>",
"      On the other hand, spinal cord stimulation was associated with a lower six-month mortality (1.9 versus 13.7 percent with CABG) and fewer cerebrovascular events (3.8 versus 15.7 percent).",
"     </li>",
"     <li>",
"      At later follow-up, cessation of spinal cord stimulation was associated with a lack of effect on ischemic ST changes but a reduction in anginal symptoms, suggesting a primary analgesic effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on chronic stable angina concluded that, although most published reports in spinal cord stimulation have shown benefit, more data are needed on intermediate and long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/54\">",
"     54",
"    </a>",
"    ]. The following data were published after the guidelines.",
"   </p>",
"   <p>",
"    The SPiRiT trial compared spinal cord stimulation to percutaneous myocardial laser revascularization in 60 patients with refractory angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/64\">",
"     64",
"    </a>",
"    ]. There was no significant difference between the groups in terms of the primary end point of total exercise time or in other parameters such as CCS functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). Although CCS functional class improved by &ge;2 CCS classes at one year in about 25 percent of patients in both groups, there was no placebo control. This is an important limitation, since the only blinded, placebo-controlled trial of percutaneous transmyocardial laser revascularization (DIRECT), using low-dose or high-dose laser channels or no laser channels blinded as a sham procedure, showed no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28167?source=see_link\">",
"     \"Transmyocardial laser revascularization for management of refractory angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with cardiac syndrome X (angina with normal coronary arteries) have frequent episodes of severe chest pain that are refractory to maximal antianginal therapy. In a small randomized crossover trial of ten such patients, spinal cord stimulation reduced the number, duration, and severity of spontaneous anginal episodes and prolonged the time to angina and to ST segment depression during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39513/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=see_link&amp;anchor=H29#H29\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\", section on 'Spinal cord stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, spinal cord stimulation is an unproven procedure given the current state of knowledge. It should be reserved for a few carefully selected patients, if any.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Transmyocardial laser revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data evaluating the efficacy of transmyocardial laser revascularization in the treatment of refractory angina are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28167?source=see_link\">",
"     \"Transmyocardial laser revascularization for management of refractory angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/35/1587?source=see_link\">",
"       \"Patient information: Medicines for angina (chest pain) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102066498\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with stable angina pectoris can have an acceptable frequency (and severity) of angina with conventional medical therapies, such as beta blockers, calcium channel blockers, nitrates,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      myocardial revascularization with either percutaneous coronary intervention (PCI) or coronary bypass graft surgery (CABG). For these patients for whom angina remains problematic, a number of medical and mechanical therapies have been evaluated for the treatment of refractory angina. Only",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"       ranolazine",
"      </a>",
"      has demonstrated significant efficacy in large trials. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/2/34854?source=see_link\">",
"       Ranolazine",
"      </a>",
"      is effective at reducing anginal symptoms and improving exercise capacity when added to conventional medical therapy. The initial dose is 500 mg twice daily. For patients who remain symptomatic, 1000 mg twice daily may be used. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ranolazine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other medical therapies such as fatty acid oxidation inhibitors or nicorandil have demonstrated some efficacy in studies. Until further supporting evidence is available, our authors do not recommend their use for the prevention of anginal episodes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enhanced external counterpulsation is the best studied of possible mechanical therapies to improve angina. While approved for use in some countries, it is not widely used. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Mechanical therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/1\">",
"      Mannheimer C, Camici P, Chester MR, et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 2002; 23:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/2\">",
"      Kim MC, Kini A, Sharma SK. Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol 2002; 39:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/3\">",
"      Yang EH, Barsness GW, Gersh BJ, et al. Current and future treatment strategies for refractory angina. Mayo Clin Proc 2004; 79:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/4\">",
"      Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006; 113:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/5\">",
"      Beyder A, Strege PR, Reyes S, et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation 2012; 125:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/6\">",
"      Stone PH. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias. Cardiol Clin 2008; 26:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/7\">",
"      Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007; 297:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/8\">",
"      Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/9\">",
"      Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/10\">",
"      Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/11\">",
"      Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/12\">",
"      Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009; 119:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/13\">",
"      \"The Pink Sheet\". Ranexa angina approval limited due to cardiac safety issue. F-D-C Reports 2006; 68:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/14\">",
"      Schram G, Zhang L, Derakhchan K, et al. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004; 142:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/15\">",
"      Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004; 9 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/16\">",
"      Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 2007; 49:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/17\">",
"      Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther 2004; 9 Suppl 1:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/18\">",
"      Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/19\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/20\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/21\">",
"      Morrow DA, Givertz MM. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005; 112:3218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/22\">",
"      Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/23\">",
"      Rosano GM, Marazzi G, Patrizi R, et al. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 2005; 95:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/24\">",
"      Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/25\">",
"      Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; :CD003614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/26\">",
"      White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol 1983; 3:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/27\">",
"      Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/28\">",
"      IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/29\">",
"      Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/30\">",
"      Rajendra NS, Ireland S, George J, et al. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 2011; 58:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/31\">",
"      Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/32\">",
"      Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/33\">",
"      Kyriakides ZS, Kremastinos DT, Kolettis TM, et al. Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Circulation 2000; 102:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/34\">",
"      Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/35\">",
"      Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/36\">",
"      Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/37\">",
"      Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/38\">",
"      Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003; 41:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/39\">",
"      Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005; 46:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/40\">",
"      Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/41\">",
"      English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/42\">",
"      van Ramshorst J, Bax JJ, Beeres SL, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009; 301:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/43\">",
"      Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/44\">",
"      Deanfield JE, Sellier P, Thaulow E, et al. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Heart J 2010; 31:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/45\">",
"      Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999; 33:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/46\">",
"      Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology 2000; 94:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/47\">",
"      Soran O, Kennard ED, Kfoury AG, et al. Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction (report from The International EECP Patient Registry). Am J Cardiol 2006; 97:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/48\">",
"      Braith RW, Conti CR, Nichols WW, et al. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation 2010; 122:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/49\">",
"      Urano H, Ikeda H, Ueno T, et al. Enhanced external counterpulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease. J Am Coll Cardiol 2001; 37:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/50\">",
"      Stys TP, Lawson WE, Hui JC, et al. Effects of enhanced external counterpulsation on stress radionuclide coronary perfusion and exercise capacity in chronic stable angina pectoris. Am J Cardiol 2002; 89:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/51\">",
"      Shechter M, Matetzky S, Feinberg MS, et al. External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris. J Am Coll Cardiol 2003; 42:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/52\">",
"      Akhtar M, Wu GF, Du ZM, et al. Effect of external counterpulsation on plasma nitric oxide and endothelin-1 levels. Am J Cardiol 2006; 98:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/53\">",
"      Nichols WW, Estrada JC, Braith RW, et al. Enhanced external counterpulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina. J Am Coll Cardiol 2006; 48:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/54\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/55\">",
"      Fraker TD Jr, Fihn SD, 2002 Chronic Stable Angina Writing Committee, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50:2264.",
"     </a>",
"    </li>",
"    <li>",
"     www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=20.20&amp;ncd_version=2&amp;basket=ncd%3A20%2E20%3A2%3AExternal+Counterpulsation+%28ECP%29+for+Severe+Angina (Accessed on August 01, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/57\">",
"      Foreman RD, Linderoth B, Ardell JL, et al. Modulation of intrinsic cardiac neurons by spinal cord stimulation: implications for its therapeutic use in angina pectoris. Cardiovasc Res 2000; 47:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/58\">",
"      Murray S, Collins PD, James MA. Neurostimulation treatment for angina pectoris. Heart 2000; 83:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/59\">",
"      TenVaarwerk IA, Jessurun GA, DeJongste MJ, et al. Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. The Working Group on Neurocardiology. Heart 1999; 82:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/60\">",
"      Murray S, Carson KG, Ewings PD, et al. Spinal cord stimulation significantly decreases the need for acute hospital admission for chest pain in patients with refractory angina pectoris. Heart 1999; 82:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/61\">",
"      Jessurun GA, DeJongste MJ, Hautvast RW, et al. Clinical follow-up after cessation of chronic electrical neuromodulation in patients with severe coronary artery disease: a prospective randomized controlled study on putative involvement of sympathetic activity. Pacing Clin Electrophysiol 1999; 22:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/62\">",
"      Mannheimer C, Eliasson T, Augustinsson LE, et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study. Circulation 1998; 97:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/63\">",
"      Norrsell H, Pilhall M, Eliasson T, Mannheimer C. Effects of spinal cord stimulation and coronary artery bypass grafting on myocardial ischemia and heart rate variability: further results from the ESBY study. Cardiology 2000; 94:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/64\">",
"      McNab D, Khan SN, Sharples LD, et al. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial. Eur Heart J 2006; 27:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/65\">",
"      Leon MB, Kornowski R, Downey WE, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005; 46:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39513/abstract/66\">",
"      Lanza GA, Sestito A, Sgueglia GA, et al. Effect of spinal cord stimulation on spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X. Eur Heart J 2005; 26:983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1524 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39513=[""].join("\n");
var outline_f38_37_39513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H102066498\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ranolazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Stable angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Unstable angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antiarrhythmic effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Glycometabolic effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inhibition of fatty acid oxidation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Trimetazidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Perhexiline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nicorandil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H271903048\">",
"      Allopurinol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endothelin receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ivabradine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fasudil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stem cell therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Therapeutic angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715362305\">",
"      High-dose statin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MECHANICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Enhanced external counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Spinal cord stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Transmyocardial laser revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102066498\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1524|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=related_link\">",
"      Allopurinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18617?source=related_link\">",
"      Genetic and cellular therapy in heart failure and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/35/1587?source=related_link\">",
"      Patient information: Medicines for angina (chest pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/20/11592?source=related_link\">",
"      Role of endothelin in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/44/27337?source=related_link\">",
"      Role of oxidative stress in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/4/6216?source=related_link\">",
"      Therapeutic angiogenesis for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28167?source=related_link\">",
"      Transmyocardial laser revascularization for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_37_39514="Diagnosis and management of late-life depression";
var content_f38_37_39514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of late-life depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     Randall T Espinoza, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     J&uuml;rgen Un&uuml;tzer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/37/39514/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/37/39514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term late-life depression includes both aging patients whose mood disorder presented in earlier life, and patients whose mood disorder presents for the first time in later life. Depressive illness in the older population is a serious health concern leading to unnecessary suffering, impaired functional status, increased mortality, and excessive use of health care resources.",
"   </p>",
"   <p>",
"    Late-life depression remains underdiagnosed and inadequately treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In the United States, older men and older African Americans and Hispanics are at even greater risk of unrecognized depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The public health consequences of inadequately treated depression in late life will increase over time as the population continues to age.",
"   </p>",
"   <p>",
"    Over 80 percent of mental health treatment for depressed older adults is delivered in the primary care setting. Depression often goes undiagnosed in primary care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/8\">",
"     8",
"    </a>",
"    ], and is often left untreated, even when diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/9\">",
"     9",
"    </a>",
"    ]. Recognition and management of late-life depression is an important responsibility for the primary care clinician.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology of late-life depression, diagnostic strategies, and options for treatment in the older adult. The diagnosis, management and prognosis of depression in the general population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38201?source=see_link\">",
"     \"Unipolar depression in adults: Prognosis and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is not a normal consequence of aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Sadness and grief are normal responses to life events that occur with aging such as bereavement; adjustment to changes in social status with retirement and loss of income; transition from independent living to assisted or residential care; and loss of physical, social, or cognitive function from illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link\">",
"     \"Grief and bereavement\"",
"    </a>",
"    .) Despite these losses, healthy independent community-dwelling elderly in the United States have a lower prevalence rate of clinical depression than the general adult population (",
"    <a class=\"graphic graphic_figure graphicRef71214 \" href=\"mobipreview.htm?25/31/26110\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of depression for community-dwelling older adults range from 2 percent (for patients in community settings who meet strict diagnostic interview criteria) to about 10 percent for patients with minor depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/13\">",
"     13",
"    </a>",
"    ]. Cultural factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/14\">",
"     14",
"    </a>",
"    ] as well as variations in methods of assessment lead to significant variations in reported prevalence. Rates of depression are higher for older adults with comorbid medical illness and in general medical settings. Hospitalized geriatric populations have prevalence rates of depression over 30 percent, and patients with stroke, myocardial infarction (MI), or cancer have rates over 40 percent (",
"    <a class=\"graphic graphic_figure graphicRef71214 \" href=\"mobipreview.htm?25/31/26110\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although prevalence of depression in the older healthy population is lower than in comparable younger groups, incidence rates may not differ. A cohort study of 5600 community dwelling persons in the Netherlands, aged 56 or older (mean age 70 years at baseline) and followed for eight years, found the incidence of depressive syndromes (major depression and dysthymia) to be 7 per 1,000 person years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/18\">",
"     18",
"    </a>",
"    ]. Most depressive episodes occurred in persons with a prior history of depression, with a recurrence rate of 25.5 per 1,000 person years. Clinically significant but subthreshold depressive symptoms occurred at twice the rate of depressive syndromes.",
"   </p>",
"   <p>",
"    The true incidence of depressive disorders in the oldest-old (&gt;85 years old) may be underestimated. This group may have an increased prevalence of depressive symptoms, although few epidemiologic studies have included participants of these ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience their first episode of depression later in life are less likely to have a family history of depression or other major mental disorder than patients whose first episode occurred earlier in life. This difference suggests that genetic or familial factors are less likely to have a role in late-onset depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Risk factors for late-life depression include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Social isolation",
"     </li>",
"     <li>",
"      Widowed, divorced, or separated marital status",
"     </li>",
"     <li>",
"      Lower socioeconomic status",
"     </li>",
"     <li>",
"      Comorbid medical conditions",
"     </li>",
"     <li>",
"      Uncontrolled pain",
"     </li>",
"     <li>",
"      Insomnia",
"     </li>",
"     <li>",
"      Functional impairment",
"     </li>",
"     <li>",
"      Cognitive impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depression occurring in the course of adverse life events was previously termed \"reactive depression\" and felt to be an expected consequence of stress or trauma. Clinical major depression should be addressed as a serious medical condition regardless of life precipitants because treatment can be effective.",
"   </p>",
"   <p>",
"    Insomnia is not only a risk factor for developing dysthymia and depression in older adults, but persistence of insomnia has been associated with persistence of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/23\">",
"     23",
"    </a>",
"    ]. Additionally, a history of sleep disturbance was an independent risk factor for recurrence of depression in older adults in remission from depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/24\">",
"     24",
"    </a>",
"    ]. Further studies are indicated to determine whether insomnia, rather than a symptom of depression, is a comorbid disorder in at least some older patients, and whether treatment for insomnia would improve depression response or prevent recurrent depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Nursing home residence",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 50 percent of nursing home residents are depressed. A study of 634,060 nursing home residents 65 years and older found that during their first year, 54 percent had physician-diagnosed depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/25\">",
"     25",
"    </a>",
"    ]. Severe cognitive impairment was associated with lower rates of depression; such impairment may interfere with detecting depression. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of depression is higher in women across all age groups. Several factors may account for the disproportionate prevalence of depression in older women: greater susceptibility to depression, greater persistence of depression after its onset, and lower mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/26\">",
"     26",
"    </a>",
"    ]. To some extent, this may also be an artifact of how depression is defined and symptoms are elicited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Men are more likely to present with anger, irritability, anhedonia, withdrawal or apathy, and alcohol abuse, and less likely to acknowledge sadness or psychological symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/30\">",
"     30",
"    </a>",
"    ]. With increasing age, the gender gap in depression prevalence narrows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/28\">",
"     28",
"    </a>",
"    ]. Men, with a higher prevalence of vascular risk factors, may present with a depression subtype known as vascular depression (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Vascular depression'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Physical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of depression in physically ill elderly increases with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent onset of physical illness",
"     </li>",
"     <li>",
"      Greater severity of physical illness",
"     </li>",
"     <li>",
"      Functional disability and limited mobility",
"     </li>",
"     <li>",
"      Poorly treated pain",
"     </li>",
"     <li>",
"      Multiple illnesses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depressed mood may be the first symptom of a number of medical conditions affecting the elderly including stroke, diabetes, cancer, hypothyroidism, and coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression amplifies disability and lessens quality of life. Late-life depression is associated with increased office and emergency department visits, increased drug use and cost for both prescription and over-the-counter medications, higher risk for use of alcohol or illicit drugs, increased length of inpatient stay, and overall higher costs of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Depression in late life also tends to be a recurrent or persistent condition and adversely impacts both medical and psychiatric morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/27,34\">",
"     27,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Medical comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of depression can have beneficial effects on health outcomes in patients with chronic medical conditions such as chronic pain, diabetes, and osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The impact of depression on medical mortality is being recognized and quantified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression onset in post-MI patients was associated with a fourfold increase in death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who developed depression after a stroke were 3.4 times more likely to have died over a 10-year follow-up period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depression at the time of admission to a nursing home increased one year mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A modified diagnosis of major depressive disorder and a past history of depression independently predicted in-hospital death with an odds ratio of 7.8 after controlling for severity of illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of depression may also impact medical mortality. A decrease in overall risk of death at five years, attributed to fewer cancer deaths, was seen in patients aged 60 and older with major depression who were randomly assigned to an intervention to improve depression treatment (involving a care manager), compared to patients assigned to a control group receiving usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Psychiatric comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbidity of depressive illness with other psychiatric syndromes such as anxiety, somatization, and substance abuse may affect overall treatment response and increase the risk of relapse and recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/2,22,43\">",
"     2,22,43",
"    </a>",
"    ]. Comorbid substance abuse with alcohol, prescription pain, or hypnotic medications is under recognized, and increases the risk of falls, accidents, and cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/3,22,43\">",
"     3,22,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comorbidity with anxiety may be a particular problem in the elderly population. The presence of anxiety with depression, especially if somatic complaints are over emphasized or primarily addressed, can lead to a missed diagnosis or inappropriate treatment with anxiolytic, hypnotic, or pain medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/3,43,44\">",
"     3,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Suicide risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is a major risk factor for suicide in the elderly, who account for about 13 percent of the United States (US) population, but for nearly 24 percent of all completed suicides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/45\">",
"     45",
"    </a>",
"    ]. Elderly patients attempt suicide less often than younger patients, but are more successful at completion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/46\">",
"     46",
"    </a>",
"    ]. Elderly men have the highest suicide rate: 28.9 per 100,000 in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/47\">",
"     47",
"    </a>",
"    ]. White men age 85 or older have the highest rate of completed suicide, 55 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/45\">",
"     45",
"    </a>",
"    ]. Most elderly suicide victims were in their first episode of depression and had seen a physician within the last month of life.",
"   </p>",
"   <p>",
"    Particular care should be paid to the elderly patient who might be at acute risk for suicide and presents with the following: hopelessness, insomnia, agitation or restlessness, impaired concentration, active psychosis, active alcohol use or intoxication, and untreated unremitting pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk factors for suicide include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/46,48,49\">",
"     46,48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Comorbid physical illness",
"     </li>",
"     <li>",
"      Chronic and inadequately treated pain",
"     </li>",
"     <li>",
"      Terminal illness or worsening of physical illness",
"     </li>",
"     <li>",
"      Widowhood and social isolation",
"     </li>",
"     <li>",
"      Personality disorders",
"     </li>",
"     <li>",
"      Prior suicide attempt",
"     </li>",
"     <li>",
"      Family history of suicide",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A collaborative care intervention for depressed older primary care patients was associated with significantly lower rates of suicidal ideation than care as usual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The field of neuropsychiatry is providing insight into the understanding of late-life depression. Damage to frontal subcortical circuitry, specifically the striato-pallido-thalamo-cortical pathways, due either to neurodegeneration or cerebrovascular disease, is implicated in some subtypes of late-life depression (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Vascular depression'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subclinical cerebrovascular disease may also influence the susceptibility to, and expression of, depression. Cerebral atrophy, subcortical deep white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/55\">",
"     55",
"    </a>",
"    ], and periventricular ischemic lesions, commonly seen on brain imaging, may be implicated. Other radiologic findings in late-life depression are increased ventricular brain ratios and decreased volumes in specific brain regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of age of onset, changes in the aging brain, and the presence of medical comorbidity influence the type and expression of depression as well as treatment responsiveness. Some patients may have clinically significant depressive symptoms but do not totally fulfill the criteria for syndromal major depression as defined by DSM-IV-TR nomenclature (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"mobipreview.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR criteria for major depression are identical for both elderly and younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/59\">",
"     59",
"    </a>",
"    ]. Of note, major depression in later life is more likely to become chronic and recovery may be more transient, leading to frequent relapses. The risk of relapse and chronicity appears heightened by extensive comorbidity.",
"   </p>",
"   <p>",
"    Elderly patients with major depression may have cognitive impairment that develops after the onset of mood symptoms, a condition previously termed pseudodementia and now referred to as dementia syndrome of depression, because the cognitive deficits are demonstrable. Antidepressant treatment can resolve the cognitive and mood symptoms of these patients. By contrast, mild to moderate depression in patients with Alzheimer disease may not respond to antidepressant therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/60\">",
"     60",
"    </a>",
"    ], or if depressive symptoms do improve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], the primary cognitive deficits of Alzheimer disease persist or become worse. It is worth noting that patients with cognitive impairment secondary to major depression may be at higher risk of converting to an irreversible dementia syndrome such as Alzheimer disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/61-65\">",
"     61-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dysthymia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients should fulfill the same criteria as younger patients, as defined by DSM-IV-TR nomenclature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/59\">",
"     59",
"    </a>",
"    ]. Dysthymia is a chronic disorder that manifests as depressive symptoms that occur on the majority of days for several years. Elderly patients with late onset dysthymia have a higher prevalence of cardiovascular disease, but are otherwise similar to older patients with late onset depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/66\">",
"     66",
"    </a>",
"    ]. Patients with dysthymia are at greater risk of developing major depression, so-called \"double-depression,\" and may be particularly treatment resistant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Subsyndromal depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may not meet DSM-IV definition for major depression (five of nine clinical symptoms) or dysthymia because of fewer symptoms or limited duration of symptoms. The problem of \"subsyndromal depressive states,\" or minor depression, is particularly important in the elderly population. These patients carry disease burdens similar to major depression, including poorer health and social outcomes, functional impairment, and higher health utilization and treatment costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Importantly, these patients are at high risk for subsequent development of major depression and may develop suicidal ideation. Subjects with minor depression, aged 60 years and older, had a 5.5-fold risk (95% CI 3.1-10) of developing major depression at one year compared to subjects without depression in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/70\">",
"     70",
"    </a>",
"    ]. Minor (or subsyndromal) depression is not currently recognized in the DSM-IV and would be diagnosed as a depressive disorder, not otherwise specified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psychotic depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar major depression with psychotic features (delusions or hallucination) is a severe subtype of unipolar major depression (major depressive disorder), which occurs as often in older patients as younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/71,72\">",
"     71,72",
"    </a>",
"    ], or more often in elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The epidemiology, clinical features, assessment, diagnosis, treatment, and prognosis of unipolar psychotic depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5368?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4105?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Acute treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Maintenance treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vascular depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease may increase an older person's vulnerability toward development of depression through a variety of neurobiological mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/51,53\">",
"     51,53",
"    </a>",
"    ]. Depression may develop after an acute cerebrovascular event (termed \"post-stroke depression\" [PSD]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/75\">",
"     75",
"    </a>",
"    ] or may develop in association with chronic ischemic changes in the brain (termed \"vascular depression\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/53,76\">",
"     53,76",
"    </a>",
"    ]. Two factors important in the development of PSD are lesion location and time from stroke. Patients with left hemisphere lesions, especially of the left prefrontal cortex, tend to have increased frequency and severity of depression. The greatest risk period from time of stroke appears to be the first two years, with peak prevalence of PSD occurring within the first three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of chronic ischemic cerebral changes is only recently recognized. A study of depressed patients with and without MRI abnormalities demonstrated that positive MRI findings correlated with older age at onset of depression, vascular comorbidity, greater psychomotor slowing or Parkinsonism, anhedonia, increased functional impairment, and lower incidence of psychosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Another study found that patients with late onset depression and cerebrovascular risk factors, compared with other late onset patients, had more cognitive impairment and disability, more psychomotor retardation, less agitation, less guilt, and less insight into their illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/53\">",
"     53",
"    </a>",
"    ]. Depressed patients with vascular risk factors have been found to be at higher risk of developing vascular dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .) Preliminary data suggest that these patients may preferentially respond to nonstandard antidepressant therapy, including older antidepressants, combination therapies, or electroconvulsive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/51,75,79\">",
"     51,75,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The syndrome of depression with executive dysfunction may also be related to cerebrovascular disease or age-related neurodegeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Patients present with frontal executive impairment manifested by difficulties with motivation, organization, planning, sequencing, and abstracting. They typically exhibit anhedonia and apathy rather than sadness, and have cognitive impairment with psychomotor retardation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alzheimer disease and other dementias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of depression either as a prodrome to Alzheimer disease (AD) or as a complication of the illness is increasingly recognized. Presentation and treatment responsiveness may significantly differ from early onset and other types of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. A proposal from the American Association for Geriatric Psychiatry suggests revised diagnostic criteria for depression in AD (",
"    <a class=\"graphic graphic_table graphicRef58421 \" href=\"mobipreview.htm?22/1/22556\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/85\">",
"     85",
"    </a>",
"    ]. Additionally, depression is a common complication in many other dementia syndromes including Parkinson Dementia, Lewy Body dementia, Frontotemporal dementia, and Huntington's dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing patients to make the diagnosis of depression in late life is challenging, especially in the physically frail elderly. Multiple factors complicate the diagnosis of depression in the elderly:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concurrent medical illness with overlapping symptoms of depression (fatigue, psychomotor slowing, loss of appetite, sleep disturbance, lack of sexual interest, memory complaints)",
"     </li>",
"     <li>",
"      Medication side effects overlapping depression symptoms",
"     </li>",
"     <li>",
"      Impaired communication skills in the elderly",
"     </li>",
"     <li>",
"      Patient presentation with multiple somatic complaints",
"     </li>",
"     <li>",
"      Lack of time in the clinical exam to evaluate psychological problems in patients with complex medical issues",
"     </li>",
"     <li>",
"      Therapeutic nihilism regarding depression on the part of the patient, family, or provider",
"     </li>",
"     <li>",
"      Patient's reluctance to acknowledge psychological distress due to perceived stigma of mental illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Depression diagnosis with medical comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few clues are helpful in diagnosing late-life depression in the setting of medical comorbidity. Depression should be considered when the following are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mood or somatic symptoms out of proportion to what is expected",
"     </li>",
"     <li>",
"      Poor response to standard medical treatment",
"     </li>",
"     <li>",
"      Poor motivation to participate in treatment",
"     </li>",
"     <li>",
"      Lack of engagement with care providers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Depression diagnosis in the frail elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphoric mood may be less reliable as an indicator of depression in the oldest old (&gt;85 years of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/30\">",
"     30",
"    </a>",
"    ]. Depression criteria in the frail elderly should emphasize a change in mood or interest with at least two weeks duration, non-physical symptoms, and social regression or incapacity. Physical symptoms used to support the diagnosis of depression should occur with or worsen after mood symptoms, and should be out of proportion to what is expected of the illness or usual treatments. Depression is less likely to be present if the patient responds to affection from family and caregivers, retains humor, looks forward to visits, and accepts assistance and care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Screening instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several screening instruments have been developed and validated for use in primary care and other settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/87\">",
"     87",
"    </a>",
"    ]. As screening tools, these should not be the sole basis for the diagnosis of depression. When a patient has a positive screen with one of the instruments, a clinical diagnostic interview should be scheduled to determine if criteria for major depression are met and if treatment is indicated.",
"   </p>",
"   <p>",
"    Table three lists characteristics of five screening tools (",
"    <a class=\"graphic graphic_table graphicRef59906 \" href=\"mobipreview.htm?41/16/42251\">",
"     table 3",
"    </a>",
"    ). Instruments vary by whether they are self- or interviewer-reported, applicable to patients with cognitive or language barriers, or validated for monitoring treatment response. These tools are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two question screener &mdash; A two question screener is easily administered and likely to identify patients at risk if both questions are answered affirmatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. The questions are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      \"During the past month, have you been bothered by feeling down, depressed or hopeless?\"",
"     </li>",
"     <li>",
"      \"During the past month, have you been bothered by little interest or pleasure in doing things?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar instrument, the Patient Health Questionnaire 2 (PHQ-2), was evaluated in a US sample of over 8,000 non-institutionalized adults aged 65 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/90\">",
"     90",
"    </a>",
"    ]. Compared against DSM-IV criteria for major depression, the PHQ-2 had a sensitivity of 100 percent and specificity of 77 percent in this population; specificity increased with age, male gender, and varied with racial and ethnic groups.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Geriatric Depression Scale &mdash; This self-report instrument has been studied in multiple settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/91,92\">",
"       91,92",
"      </a>",
"      ]. A five-item version demonstrated good receiver operating characteristics across the full spectrum of elderly populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/92\">",
"       92",
"      </a>",
"      ]. The five items are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Are you basically satisfied with your life?",
"     </li>",
"     <li>",
"      Do you often get bored?",
"     </li>",
"     <li>",
"      Do you often feel helpless?",
"     </li>",
"     <li>",
"      Do you prefer to stay at home rather than going out and doing new things?",
"     </li>",
"     <li>",
"      Do you feel pretty worthless the way you are now?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two out of five depressive responses (\"no\" to question 1 or \"yes\" to questions 2 through 5) suggests the diagnosis of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PHQ-9 &mdash; This was developed specifically for use in primary care settings and has demonstrated ease, validity, and reliability (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/94\">",
"       94",
"      </a>",
"      ]. It covers all nine DSM-IV criteria for major depression and can be used to help establish a diagnosis of major depression. The PHQ-9 was shown to be a reliable measure of depression treatment outcomes in a large study of older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/95\">",
"       95",
"      </a>",
"      ]. The tool can be used to assess response to treatment in individual patient care.",
"     </li>",
"     <li>",
"      Cornell Scale for Depression in Dementia &mdash; This incorporates both observer and informant based information and is helpful in evaluating cognitively impaired patients for depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Center for Epidemiologic Studies&nbsp;Depression Scale &mdash; This is one of the most common instruments applied in community studies and commonly used in primary care settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/97,98\">",
"       97,98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of depression in late life is dependent upon several factors: addressing comorbid conditions, tailoring pharmacologic or other interventions to the individual patient, monitoring therapy for side effects and effectiveness, and assuring close follow-up. Consultation with a mental health specialist should be considered for patients who have failed multiple trials of antidepressants or who have a preference for non-pharmacologic treatment.",
"   </p>",
"   <p>",
"    A complete history will guide treatment decisions. Aspects of the history of special importance in managing depression in the elderly are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment for suicidality, including ideation and plan (lethality, intent, and means). Acute suicidal ideation requires urgent psychiatric referral [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assessment for psychotic symptoms, hopelessness, insomnia, and malnutrition.",
"     </li>",
"     <li>",
"      Determination of whether the patient is using medication(s) with depressant side effects (benzodiazepines, CNS depressants, opiates, other pain medications) or is abusing alcohol.",
"     </li>",
"     <li>",
"      Consideration of other medical conditions commonly associated with depressive symptoms, particularly unrecognized thyroid disease, or diabetes. Additionally, pain syndromes can be a barrier to treatment response in depression and should be treated along with the depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Determination of history of prior depressive episodes, age of depression onset, prior drug therapy and outcome, and length of prior remission if achieved.",
"     </li>",
"     <li>",
"      Determination of a family history of depression and family response to medication. Older patients with mild depressive symptoms and first degree relatives with confirmed depression diagnosis have a 1.5 to 3 times greater risk for depression than the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of depression consists of psychotherapy and somatic therapy (medication or electroconvulsive therapy). A meta-analysis of 89 controlled studies involving older adults with depression of varied severity (major depression, minor depression and dysthymia) found that well-designed randomized studies were limited, but that the overall effect size of either psychotherapy or medication was moderate to large, and roughly equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/101\">",
"     101",
"    </a>",
"    ]. The choice of treatment will depend upon the type and chronicity of the depressive episode, contraindications to medication, treatment access, and patient preference. Psychotherapy and pharmacotherapy may be used singly or in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/102\">",
"     102",
"    </a>",
"    ]. For moderate to severe forms of depression, we recommend pharmacotherapy. For chronic forms of depression, the combination of pharmacotherapy and psychotherapy may be most effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies suggest that treatment programs that offer a choice of medication",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychotherapy in primary care, often combined with patient outreach by a care manager in a collaborative care model, have significantly better outcomes than usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/50,104-106\">",
"     50,104-106",
"    </a>",
"    ]. The Improving Mood Promoting Access to Collaborative Treatment (IMPACT) program for late-life depression has been shown to be more cost effective than usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/106\">",
"     106",
"    </a>",
"    ], to significantly improve outcomes for depressed elders (symptoms, physical functioning, quality of life) that were sustained one year after termination of the collaborative intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/107\">",
"     107",
"    </a>",
"    ], and to decrease suicidal ideation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although antidepressants are efficacious for late-life major depression, efficacy may possibly be reduced in older late-life major depression. A meta-analysis of 15 randomized trials compared antidepressants with placebo in 4756 patients with major depression, aged 55 years and older (mean age 70 years). Response (improvement from baseline on the depression rating scale &ge; 50 percent) was greater with antidepressants (relative risk 1.3, 95% CI 1.2-1.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/109\">",
"     109",
"    </a>",
"    ]. However, in the meta-analysis of six trials (1840 patients) that used a minimum age of 65 or 75 years (mean age 74 years), response was comparable for antidepressants and placebo. Both meta-analyses were limited by statistically significant heterogeneity among the combined trials, the lack of any trials that focused upon patients older than 80 years, and the probable exclusion of more severely depressed patients. &nbsp;",
"   </p>",
"   <p>",
"    Exercise may be effective in the treatment of minor or major depression in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/110\">",
"     110",
"    </a>",
"    ]. Patients with major depression, however, may be difficult to engage in an exercise program and would likely benefit from concomitant pharmacotherapy or psychotherapy. Exercise is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Exercise'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapy is a useful but frequently underutilized treatment for elderly depressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/102,111\">",
"     102,111",
"    </a>",
"    ]. The availability of adequately trained therapists is a limiting factor, and health insurance coverage for psychotherapy is often incomplete. Available modalities include individual, couples, family, or group therapy. Settings include private offices, community senior centers, partial hospital day programs or intensive outpatient group programs. The discussion below focuses on the efficacy of psychotherapy in older adults; a general discussion of psychotherapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term treatments include cognitive-behavioral therapy (CBT), interpersonal psychotherapy, and problem-solving therapy, which are delivered over a period of two to four months and are effective for older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/112-116\">",
"     112-116",
"    </a>",
"    ]. CBT is the most widely studied psychotherapy. A meta-analysis of 10 randomized trials (380 elderly depressed patients) found a significant, clinically large effect favoring CBT over treatment as usual or waiting list controls; heterogeneity across studies was small to moderate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/117\">",
"     117",
"    </a>",
"    ]. A prior meta-analysis of three trials found that improvement of depression was comparable for CBT and interpersonal psychotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/116\">",
"     116",
"    </a>",
"    ]. Additional information about the efficacy of interpersonal psychotherapy for elderly depressed patients is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17674?source=see_link&amp;anchor=H2291321#H2291321\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Older patients'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Multiple trials have found problem-solving therapy can be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/104\">",
"     104",
"    </a>",
"    ]. As an example, a 12 week randomized trial compared problem-solving therapy with a control therapy in 221 non-demented patients aged &ge;60 years with major depression and executive dysfunction (difficulty with goal setting and planning, and with initiating and sequencing behavior) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Executive dysfunction is associated with poor response to antidepressants. Remission of depression occurred in more patients who received problem-solving therapy compared with controls (46 versus 28 percent). In addition, improvement of disability (self-care, communicating, and psychosocial functioning) was significantly greater with problem-solving therapy, and the advantage was retained at the 24-week follow-up after the end of treatment. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Patients with early, mild stage Alzheimer disease may benefit from a therapeutic approach that includes a life-reminiscing component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/120\">",
"     120",
"    </a>",
"    ]. Caregivers of patients with Alzheimer disease are at high risk for depression and burnout and also respond well to psychotherapy in both individual and support group modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychotherapy and community-based programs for older adults may be particularly helpful for patients with minor depression, for whom pharmacologic intervention has not demonstrated consistent effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/70,117\">",
"     70,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Treatment for anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;One randomized trial of elder patients with generalized anxiety disorder found that cognitive behavioral therapy (CBT) delivered in the primary care setting by clinicians with expertise in CBT, compared with enhanced usual care (biweekly telephone contact), decreased worry symptoms and moderately improved depressive symptoms in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/122\">",
"     122",
"    </a>",
"    ]. Whether CBT is effective for anxiety in association with major depression has not been studied in randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Medication acceptance by patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many older patients are reluctant to take medication for their depression. Interviews with patients 60 years and older with depression (n = 68) found the following concerns expressed: fear of medication dependence, rejection of concept of depression as a medical illness, belief that medications would inhibit normal emotional reactions, and prior negative experience with medications for depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/123\">",
"     123",
"    </a>",
"    ]. Understanding why a patient may be reluctant to initiate medication can promote clinician-patient dialogue to address their specific concerns and initiate effective treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Medication selection and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of 26 randomized trials comparing antidepressant classes in patients aged 55 and older found little difference in efficacy between medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/124\">",
"     124",
"    </a>",
"    ]. However, there was a higher withdrawal rate due to side effects for patients treated with tricyclic antidepressants, compared with selective serotonin reuptake inhibitors (SSRIs). These findings suggest that side effect profiles should be the major determinant in medication selection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications typically take up to four to six weeks to show efficacy. In elderly patients a full antidepressant response may not occur until 8 to 12 or even 16 weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/125,127,128\">",
"     125,127,128",
"    </a>",
"    ]. However, one study of 472 older patients with major depression found that patients who had no improvement at all by 4 weeks of treatment were unlikely to respond even after 8 additional weeks, and would be candidates for an early change in their treatment plan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monotherapy is preferred in the elderly in order to minimize drug side effects and drug-drug interactions. Although one non-randomized open label study demonstrated good response to augmentation for treatment-resistant older patients with no medical contraindication to augmentation medications (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/130\">",
"     130",
"    </a>",
"    ], combination strategies for augmented or accelerated responses in the elderly are preferably avoided in the primary care setting.",
"   </p>",
"   <p>",
"    Initial medication dosage should be adjusted for the older adult, typically cutting the usual starting dose for younger patients in half. Lower starting doses will compensate for decreased drug clearance in the elderly, minimize initial side effects, and promote medication compliance and maintenance. However, under-treatment of elderly depressed patients is well documented; it is important to reach the same therapeutic dosage range as in younger adults in order to maximize the chances of achieving complete remission.",
"   </p>",
"   <p>",
"    Patients should be contacted or seen within two weeks of initiating medication to discuss tolerance, address concerns, and adjust dose as indicated. Patients should have an office visit within two to four weeks of initiation of medication treatment to assess for response, complications, or deterioration. Depression-specific case management, (involving specially trained nurses or social workers collaborating with primary care physicians to assist with depression identification, guideline-based treatment and follow-up) was effective, compared with usual care, in reducing mortality and depressive symptoms in older patients with major depression in a randomized trial involving 20 primary care practices in three US cities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discussion below is an overview of antidepressant use in the elderly. Antidepressant pharmacology and management is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual course of treatment for the first lifetime episode of unipolar major depression in adults is 6 to 12 months beyond the time of achieving full remission. The goal of continuation and maintenance treatment is to prevent relapse. Relapse rates in the elderly are higher than in younger populations, which may indicate a need for longer periods of maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/132\">",
"     132",
"    </a>",
"    ]. Prior to discontinuing maintenance treatment, clinicians should educate patients about monitoring themselves for symptoms of recurrent episodes, and restarting treatment if symptoms recur.",
"   </p>",
"   <p>",
"    Evidence for the efficacy of maintenance treatment includes a meta-analysis of six randomized trials that compared antidepressants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , dothiepin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ) with placebo for up to three years in 708 elderly patients who remitted from unipolar major depressive episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/133\">",
"     133",
"    </a>",
"    ]. Recurrent episodes occurred in fewer patients who received antidepressants than placebo (37 versus 59 percent). In addition, discontinuation of treatment due to side effects was comparable.",
"   </p>",
"   <p>",
"    Maintenance treatment with monthly psychotherapy, either alone or as add-on treatment with pharmacotherapy, does not appear to be effective for preventing recurrent late life depressive episodes. As an example, a two year randomized maintenance trial found that interpersonal psychotherapy did not prevent recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/134\">",
"     134",
"    </a>",
"    ]. Among patients 70 years of age and older who had responded to treatment for unipolar major depression (N = 116) and were then assigned to one of four maintenance treatments, the rate of recurrence was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      (10 to 40 mg per day) plus monthly interpersonal psychotherapy &ndash; 35 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      plus monthly \"sham\" psychotherapy (clinical management sessions) &ndash; 37 percent",
"     </li>",
"     <li>",
"      Pill placebo plus psychotherapy &ndash; 68 percent",
"     </li>",
"     <li>",
"      Placebo plus clinical management &ndash; 58 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For older patients who experience frequent relapses or recurrences, or who have dysthymic disorder, long-term treatment may be needed; for patients requiring continuous treatment beyond two to three years, consultation with a psychiatrist may be helpful. Studies in adult populations younger than age 65 suggest that chronic antidepressant therapy should be considered for patients with three or more serious episodes of depression before age 50. However, similar data are lacking for treatment of recurrent depression in older populations and consultation with a psychiatrist may be helpful in such cases, too.",
"   </p>",
"   <p>",
"    Discontinuing antidepressants may be prompted by tachyphylaxis or side effects, or by the need to initiate another medication that may cause a drug-drug interaction with the existing antidepressant. Development of an intercurrent illness, especially of major organ, cerebral, or systemic disease, may also make continuation of antidepressants problematic. Long term safety data on chronic antidepressant use in the elderly with chronic comorbid medical conditions are lacking.",
"   </p>",
"   <p>",
"    Additional information about continuation and maintenance treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/39/9850?source=see_link\">",
"     \"Unipolar depression in adults: Continuation and maintenance treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Antidepressant medications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Selective serotonin reuptake inhibitors (SSRIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs are considered first line for treatment of depressive disorders in older adults due to better tolerability, ease of use, and general safety, especially in overdose (",
"    <a class=\"graphic graphic_table graphicRef57207 \" href=\"mobipreview.htm?36/12/37070\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resolution of depressive symptoms, usually between four to six weeks, may take longer in the elderly. Potential side effects of SSRIs of special concern in the elderly include Parkinsonism, akathisia, anorexia, sinus bradycardia, and hyponatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/135\">",
"     135",
"    </a>",
"    ]. A dose-related increased risk for fragility fractures (fractures resulting from minimal trauma) was reported in one observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/136\">",
"     136",
"    </a>",
"    ]. Risk factors may include extensive medical or neurologic comorbidity or concurrent use of multiple medications. Careful monitoring is advised in more frail populations.",
"   </p>",
"   <p>",
"    One study did suggest an increased rate of suicide in men 66 years and older in the first month of treatment with an SSRI, compared to other antidepressant drugs; this effect was not seen during subsequent treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/137\">",
"     137",
"    </a>",
"    ]. Monitoring for suicide risk is recommended in early therapy with an SSRI. Nonetheless, and as previously noted, treating depression can reduce suicidal ideation (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Suicide risk'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/50,138\">",
"     50,138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite greater acceptance and clinical recommendations, SSRIs are probably not more efficacious than older antidepressants. Comparison studies in the elderly show that the difference in clinical efficacy is small, the range of placebo response is broad, and that a significant number of elderly retain significant residual depressive symptomatology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]. For severe forms of melancholic and psychotic depression, SSRI agents may be less efficacious than other drugs or electroconvulsive therapy (ECT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/126,139\">",
"     126,139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration issued warnings that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    causes dose-dependent QT interval prolongation that can lead to arrhythmias, and thus recommends that the maximum dose in patients &gt;60 years of age should not exceed 20 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/140,141\">",
"     140,141",
"    </a>",
"    ]. Additional information about the citalopram warnings and cardiac effects of SSRIs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Serotonin-norepinephrine reuptake inhibitors (SNRIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , two available serotonin-norepinephrine reuptake inhibitors (SNRIs), are currently used as second-line agents for treatment failure with SSRIs (",
"    <a class=\"graphic graphic_table graphicRef57207 \" href=\"mobipreview.htm?36/12/37070\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These agents may also be useful in patients with comorbid pain. In a 9 week randomized study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    and placebo for treatment of major depression in patients over age 55, the duloxetine group had a greater treatment response for depression as well as reduction in overall pain, back pain, and pain while awake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/142\">",
"     142",
"    </a>",
"    ]. However, discontinuation due to adverse events was significantly greater in the duloxetine group (21 percent compared to 7 percent).",
"   </p>",
"   <p>",
"    Few comparison studies exist between SSRIs and SNRIs in the elderly. Frail nursing home patients showed a poorer tolerance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    when compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SNRIs are considered safe for use in most elderly populations, although both carry a dose-dependent risk for diastolic hypertension. In a study of older adults,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    extended-release (XR) was found to cause less GI distress and agitation than the immediate release preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    , another agent with serotonergic and noradrenergic properties, is also used as a second line agent. Mirtazapine appears to be useful for elderly patients with insomnia, agitation or restlessness, and anorexia or weight loss. It may also be useful in patients with Parkinsonism, essential tremor, or nausea from chemotherapy, and is available as a rapidly dissolving sol-tab preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    include sedation, especially at initiation and at lower dosages, appetite increase and weight gain, dry mouth, and constipation. The sedating effects of mirtazapine tend to diminish with acclimation and also tend to be less pronounced at higher dosages where the noradrenergic effects predominate over the antihistaminergic effects.",
"   </p>",
"   <p>",
"    The SNRIs, as well as SSRIs, have resulted in the serotonin syndrome, but more data are needed to identify risk factors for elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/146\">",
"     146",
"    </a>",
"    ]. Serotonin syndrome manifests as altered mental status, myoclonus, tremors, hyperreflexia, fever, and autonomic changes among other findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/147,148\">",
"     147,148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Atypical antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;This group is comprised of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef57207 \" href=\"mobipreview.htm?36/12/37070\">",
"     table 5",
"    </a>",
"    ). Few studies exist in populations of elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is generally considered an activating agent, so it may be useful in patients who complain of lethargy, daytime sedation, or fatigue. Bupropion is contraindicated in patients with seizure disorders, concurrent use of benzodiazepines or other CNS depressants, alcohol detoxification, or prior or current diagnosis of bulimia nervosa. Dose-dependent diastolic hypertension is a concern in the older patient.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     Nefazodone",
"    </a>",
"    is available in the US in a generic preparation only, as the brand (Serzone) was voluntarily removed from the market due to hepatotoxicity concerns. Nefazodone has been withdrawn from several countries outside the US, including European countries and Canada. Common side effects include sedation and restlessness. It appears to have relatively good GI tolerance. Nefazodone may be useful in depressed patients who complain of insomnia, anxiety, or agitation. Nefazodone is a potent inhibitor of the CYP450-3A4 isoenzyme, so significant drug-drug interactions may occur with commonly used macrolide antibiotics, cardiac antiarrhythmics, and other psychotropic agents.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    is rarely used solely as an antidepressant but is still commonly used as a soporific and mild sedative, especially at lower doses. Antidepressant effects tend to be seen only at higher dosages, where concerns about orthostatic hypotension and excessive daytime sedation limit its use. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     nefazodone",
"    </a>",
"    and trazodone have been associated with hyponatremia and trazodone has been associated with the rare but potentially serious side effect of priapism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Agomelatine was approved for use in Europe in 2009 but is not approved in the United States. A review identified only one controlled trial (unpublished) in the elderly, in which 218 patients 60 years and older with major depression, were randomly assigned to agomelatine 25 mg per day or placebo for six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/150\">",
"     150",
"    </a>",
"    ]. There was no significant difference in Montgomery Asberg Depression Rating Scale scores. In addition, the rate of response, defined by at least a 50 percent decrease in scores, did not differ significantly between agomelatine and placebo (46 versus 52 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Tricyclic and tetracyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;While no longer considered first or second-line agents for the treatment of depression in any age group, these agents may be useful for treatment failure with other antidepressants (",
"    <a class=\"graphic graphic_table graphicRef57207 \" href=\"mobipreview.htm?36/12/37070\">",
"     table 5",
"    </a>",
"    ). A few studies suggest that cyclic antidepressants may have superior efficacy in the elderly with melancholic or delusional depression, and these antidepressants are the only class shown to reduce the risk of relapse after a course of electroconvulsive therapy (ECT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/128,139,151\">",
"     128,139,151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cyclic antidepressants must be used cautiously in patients with cardiac conduction abnormalities, arrhythmias, narrow angle glaucoma, urinary retention, or BPH, and patients should be followed for development or worsening of orthostatic hypotension and constipation. Additionally, patients with Alzheimer-type dementia may experience worsening confusion. Tricyclic and tetracyclic antidepressants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Monoamine oxidase inhibitors (MAOIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This class of antidepressants is rarely used except when previously initiated and tolerated, or in the patient who is treatment resistant to all other antidepressants (",
"    <a class=\"graphic graphic_table graphicRef78169 \" href=\"mobipreview.htm?32/53/33627\">",
"     table 6",
"    </a>",
"    ). MAOIs do have proven benefit, with some studies suggesting superior efficacy in atypical (reverse neurovegetative) depression, mixed anxiety-depressive states, and panic disorder, although limited research studies are found in elderly populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with MAOIs require special dietary and medication restrictions to prevent the serotonin syndrome and hyperadrenergic crisis. Because of potential severe side effects, these medications are best prescribed by a psychiatrist or physician with extensive experience in use of these medications. Aside from these concerns, these medications are surprisingly well tolerated in the elderly. Common side effects include orthostatic hypotension, activation, and insomnia. In contrast to TCAs, these medications are relatively devoid of cardiac conduction effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2540898\">",
"    <span class=\"h2\">",
"     Quetiapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the second-generation antipsychotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    may be effective for major depression, the risk of short- and long-term side effects is such that quetiapine is not a first or second line treatment. Evidence for the efficacy of quetiapine includes a nine week randomized trial that compared quetiapine extended release monotherapy (50 to 300 mg per day, median dose 159 mg per day) with placebo in 335 patients with late-life, nonpsychotic, unipolar major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/153\">",
"     153",
"    </a>",
"    ]. Remission occurred in more patients who received quetiapine than placebo (45 versus 17 percent). Discontinuation of treatment following an adverse event occurred in more than twice as many patients who received quetiapine (10 versus 4 percent). Common side effects of quetiapine included sedation, dry mouth, and extrapyramidal symptoms. Although these findings indicate that quetiapine extended release may have some utility for major depression, ongoing concerns remain about safety issues and side effects, especially with long term treatment. The use of second-generation antipsychotics as adjunctive treatment for unipolar major depression that does not respond to antidepressant monotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31993?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with second-generation antipsychotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21628528\">",
"    <span class=\"h2\">",
"     Neurostimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several brain stimulation procedures for treating major depression are clinically available or under investigation. An overview of these procedures is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/30/6633?source=see_link\">",
"     \"Unipolar depression in adults: Overview of neuromodulation procedures\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Electroconvulsive therapy (ECT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT remains an important and viable treatment option in the elderly. ECT is used for depressed patients who have not responded to adequate antidepressant trials, and patients with severe major depression that is life-threatening or significantly impairs functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/79,154-157\">",
"     79,154-157",
"    </a>",
"    ]. Indications for use, description of the procedure, morbidity, and risk assessment for ECT are discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41416?source=see_link&amp;anchor=H11#H11\">",
"     \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\", section on 'Age'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Other brain stimulation therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other brain stimulation therapies have been evaluated for treatment of medication resistant depression; these therapies include repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS). However, there are no randomized trials that have demonstrated any benefit of these modalities in the elderly. Neuromodulation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/30/6633?source=see_link\">",
"     \"Unipolar depression in adults: Overview of neuromodulation procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16682?source=see_link&amp;anchor=H31837820#H31837820\">",
"     \"Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)\", section on 'Elderly'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5097?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with surgical approaches\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of controlled trials indicate that physical exercise is beneficial for depressed patients 60 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/110,158,159\">",
"     110,158,159",
"    </a>",
"    ]. As an example, one review of 11 studies found short-term benefits in nine studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical exercise may be a first-line treatment for patients with mild or moderate depression, but it may be difficult for them to engage in exercise. Thus, additional treatment with medications or psychotherapy may be needed.",
"   </p>",
"   <p>",
"    The two main types of exercise are cardiovascular (aerobic) activities such as walking, running, or swimming, and resistance training (nonaerobic) that involves lifting weights. Both types of exercise can help reduce depressive symptoms, but the results appear to be more consistent for cardiovascular exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/158\">",
"     158",
"    </a>",
"    ]. One review found that late-life depressive symptoms were substantially reduced in more patients who participated in short-term (eg 12-week), supervised, group-based, cardiovascular exercise programs, compared with patients in control groups (45 to 65 versus 25 to 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of exercise appear to persist in depressed, older patients who continue to exercise for the long term. A study randomly assigned 438 adults with osteoarthritis, 60 years or older, to cardiovascular exercise, resistance exercise, or health education classes (to control for the therapeutic effects of socialization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/160\">",
"     160",
"    </a>",
"    ]. The exercise programs were conducted under supervision for three months in a facility, and then for 15 months at home with face-to-face or telephone contact by the exercise leader. Among the 98 patients with major depression, the reduction in depression rating scale scores at month 18 was significantly greater for those assigned to cardiovascular exercise compared with health education (40 versus 20 percent reduction). Resistance exercise did not differ significantly from health education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3262160\">",
"    <span class=\"h2\">",
"     Bright light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bright light therapy may be beneficial for depressed patients who do not have seasonal affective disorder. A three week randomized trial compared bright light treatment (pale blue, approximately 7500 lux) with placebo (dim red, approximately 50 lux) in 89 elderly patients with nonseasonal major depression. Response (improvement from baseline &ge;50 percent) occurred in more patients who received bright light (58 versus 34 percent), which was well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3262263\">",
"    <span class=\"h2\">",
"     Collaborative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collaborative care programs emphasize patient education and use non-physician mental health professionals or depression care managers to integrate psychiatric and primary care; these collaborative programs for elderly depressed patients can enhance outcomes compared with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/162\">",
"     162",
"    </a>",
"    ]. As an example, a six month randomized trial compared care management plus pharmacotherapy with pharmacotherapy alone in 57 patients with a depressive disorder, aged 60 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/163\">",
"     163",
"    </a>",
"    ]. Care management consisted of eight telephone calls from a psychologist, who educated patients about depression, treatment options, and adherence; monitored symptoms and adverse events; and reminded patients about their next visit to the clinic. Remission occurred in more patients who received care management plus pharmacotherapy than pharmacotherapy alone (55 versus 29 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3262478\">",
"    <span class=\"h2\">",
"     Family support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members should be involved in the care of patients with late-life major depression, and be educated about the signs and symptoms, treatment, and prognosis of the illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/162\">",
"     162",
"    </a>",
"    ]. The family can provide information about symptoms that the patient may not reveal and can encourage adherence to treatment. Family meetings for assessment and treatment of patients with major depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18025?source=see_link\">",
"     \"Family and couples therapy for treating depressed adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88015669\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive impairment in late-life depression raises the question as to whether cholinesterase inhibitors are useful. A randomized trial compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    with placebo as adjunctive maintenance treatment in adults aged 65 years and older treated with an antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/37/39514/abstract/164\">",
"     164",
"    </a>",
"    ]. Cognitive functioning was superior with donepezil at one year but not two years. However, donepezil appeared to increase the risk of recurrence of major depression. Thus, its use in this population requires close monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Epidemiology and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late-life depression often goes undetected and has a significant adverse impact on quality of life, outcomes of medical disease, healthcare utilization, and morbidity and mortality. The overwhelming majority of older adults with depression initially present to primary care, often with somatic complaints.",
"     </li>",
"     <li>",
"      Depression is not a normal consequence of aging. Healthy independent elders have a lower prevalence rate of major depression than the general population. Rates increase greatly with medical illness, particularly cancer, MI, and neurological disorders such as stroke and Parkinson disease (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Suicide rates are almost twice as high in the elderly, with the rate highest for white men over 85 years of age. Most older adults who commit suicide had seen a clinician within the previous month (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Suicide risk'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      \"Minor\" or \"subsyndromal\" depression in late life is more prevalent than major depression, has significant health consequences, and responds to antidepressant medication or psychotherapy (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Subsyndromal depression'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Delusional (psychotic) depression is a very severe illness and can be lethal. Cognitive deficits may be pronounced and similar to dementia. However, both depressive symptoms and cognitive impairment respond to treatment with antidepressants, distinguishing these patients from those with Alzheimer disease and secondary depression (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Psychotic depression'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Depression associated with cerebrovascular disease is characterized by psychomotor retardation, anhedonia, greater frontal executive dysfunction, and poor insight (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Vascular depression'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Depression in the elderly can be challenging to diagnose. Screening instruments are available that can help identify patients who need further evaluation for depression (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Screening instruments'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychotherapy is effective in older adults, although for moderate to severe depression in late life, pharmacotherapy or a combination of pharmacotherapy and psychotherapy is recommended (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Psychotherapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Medication monotherapy is preferred in the elderly in order to minimize drug side effects and drug-drug interactions. Initial medication dosage should be adjusted for the older adult, typically halving the usual starting dose for younger patients but full therapeutic doses are often required to achieve the desired responses (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Medication selection and management'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      All medications typically take four to six weeks to show efficacy; in elderly patients a full antidepressant response may not occur until 8 to 12 or even 16 weeks of therapy. Long-term treatment may be necessary to prevent recurrence (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Medication selection and management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Duration of treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients should be contacted or seen within two weeks of initiating medication to discuss tolerance and adjust dose as indicated, and should have an office visit within two to four weeks of treatment to assess response, monitor for side-effects, and address any complications or deterioration",
"     </li>",
"     <li>",
"      SSRI medications are considered first line treatment because of safety and tolerability. However, in patients aged 60 years and above, the maximum recommended dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      is 20 mg per day due to concerns about dose-dependent QT interval prolongation that can lead to arrhythmias. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Selective serotonin reuptake inhibitors (SSRIs)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       Mirtazapine",
"      </a>",
"      may be useful for patients with insomnia, agitation, restlessness, or anorexia and weight loss.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      are frequently used as second line agents and may be particularly helpful in patients with depression and neuropathic pain (see",
"      <a class=\"local\" href=\"#H31\">",
"       'Serotonin-norepinephrine reuptake inhibitors (SNRIs)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Tricyclic antidepressants are third- or fourth-line therapy in the elderly due to significant arrhythmic side effects, as well as anticholinergic effects causing urinary retention, orthostasis, and possible exacerbation of dementia. These drugs, when necessary, are probably best managed by a psychiatrist or physician with special expertise and experience in managing these medications in the elderly (see",
"      <a class=\"local\" href=\"#H33\">",
"       'Tricyclic and tetracyclic antidepressants'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      MAO inhibitors can be used for depression that is resistant to other agents. This class of drugs has not been well studied in the elderly. They should also be prescribed by a psychiatrist or physician with special expertise and experience with these medications, because of their serious side effect profile (see",
"      <a class=\"local\" href=\"#H34\">",
"       'Monoamine oxidase inhibitors (MAOIs)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      ECT is used more frequently in the elderly than in younger patients, and may be effective for the older patient who is intolerant of medications or not responding to adequate medication trials. ECT is generally well tolerated in the older patient, although it causes transient memory loss (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41416?source=see_link&amp;anchor=H11#H11\">",
"       \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\", section on 'Age'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/1\">",
"      Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life. Consensus statement update. JAMA 1997; 278:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/2\">",
"      Hybels CF, Blazer DG. Epidemiology of late-life mental disorders. Clin Geriatr Med 2003; 19:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/3\">",
"      Valenstein M, Taylor KK, Austin K, et al. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry 2004; 161:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/4\">",
"      Un&uuml;tzer J. Clinical practice. Late-life depression. N Engl J Med 2007; 357:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/5\">",
"      Fyffe DC, Sirey JA, Heo M, Bruce ML. Late-life depression among black and white elderly homecare patients. Am J Geriatr Psychiatry 2004; 12:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/6\">",
"      Crystal S, Sambamoorthi U, Walkup JT, Akincigil A. Diagnosis and treatment of depression in the elderly medicare population: predictors, disparities, and trends. J Am Geriatr Soc 2003; 51:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/7\">",
"      Un&uuml;tzer J, Katon W, Callahan CM, et al. Depression treatment in a sample of 1,801 depressed older adults in primary care. J Am Geriatr Soc 2003; 51:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/8\">",
"      Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a population-based sample of depressed elderly patients. Arch Gen Psychiatry 2003; 60:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/9\">",
"      Licht-Strunk E, Van Marwijk HW, Hoekstra T, et al. Outcome of depression in later life in primary care: longitudinal cohort study with three years' follow-up. BMJ 2009; 338:a3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/10\">",
"      Steffens DC, Skoog I, Norton MC, et al. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 2000; 57:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/11\">",
"      Koenig HG, Blazer DG. Epidemiology of geriatric affective disorders. Clin Geriatr Med 1992; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/12\">",
"      Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Physician 2004; 69:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/13\">",
"      Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry 1999; 174:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/14\">",
"      Castro-Costa E, Dewey M, Stewart R, et al. Prevalence of depressive symptoms and syndromes in later life in ten European countries: the SHARE study. Br J Psychiatry 2007; 191:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/15\">",
"      Koenig HG, George LK, Peterson BL, Pieper CF. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 1997; 154:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/16\">",
"      Burke WJ, Wengel SP. Late-life mood disorders. Clin Geriatr Med 2003; 19:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/17\">",
"      Borin L, Menon K, Raskin A, Ruskin P. Predictors of depression in geriatric medically ill inpatients. Int J Psychiatry Med 2001; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/18\">",
"      Luijendijk HJ, van den Berg JF, Dekker MJ, et al. Incidence and recurrence of late-life depression. Arch Gen Psychiatry 2008; 65:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/19\">",
"      Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994; 151:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/20\">",
"      Beekman AT, Geerlings SW, Deeg DJ, et al. The natural history of late-life depression: a 6-year prospective study in the community. Arch Gen Psychiatry 2002; 59:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/21\">",
"      Reynolds CF 3rd, Dew MA, Frank E, et al. Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 1998; 155:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/22\">",
"      Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry 2003; 160:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/23\">",
"      Pigeon WR, Hegel M, Un&uuml;tzer J, et al. Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort? Sleep 2008; 31:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/24\">",
"      Cho HJ, Lavretsky H, Olmstead R, et al. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry 2008; 165:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/25\">",
"      Hoover DR, Siegel M, Lucas J, et al. Depression in the first year of stay for elderly long-term nursing home residents in the USA. Int Psychogeriatr 2010; 22:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/26\">",
"      Barry LC, Allore HG, Guo Z, et al. Higher burden of depression among older women: the effect of onset, persistence, and mortality over time. Arch Gen Psychiatry 2008; 65:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/27\">",
"      Schoevers RA, Geerlings MI, Beekman AT, et al. Association of depression and gender with mortality in old age. Results from the Amsterdam Study of the Elderly (AMSTEL). Br J Psychiatry 2000; 177:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/28\">",
"      Kornstein SG. Gender differences in depression: implications for treatment. J Clin Psychiatry 1997; 58 Suppl 15:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/29\">",
"      Crossett JH. The best is yet to be: preventing, detecting, and treating depression in older women. J Am Med Womens Assoc 2004; 59:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/30\">",
"      Gallo JJ, Rabins PV, Lyketsos CG, et al. Depression without sadness: functional outcomes of nondysphoric depression in later life. J Am Geriatr Soc 1997; 45:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/31\">",
"      Polsky D, Doshi JA, Marcus S, et al. Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med 2005; 165:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/32\">",
"      Un&uuml;tzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA 1997; 277:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/33\">",
"      Un&uuml;tzer J, Schoenbaum M, Katon WJ, et al. Healthcare costs associated with depression in medically Ill fee-for-service medicare participants. J Am Geriatr Soc 2009; 57:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/34\">",
"      Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA 2001; 286:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/35\">",
"      Lin EH, Katon W, Von Korff M, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. JAMA 2003; 290:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/36\">",
"      Williams JW Jr, Katon W, Lin EH, et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med 2004; 140:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/37\">",
"      Frasure-Smith N, Lesp&eacute;rance F, Juneau M, et al. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999; 61:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/38\">",
"      Whyte EM, Mulsant BH, Vanderbilt J, et al. Depression after stroke: a prospective epidemiological study. J Am Geriatr Soc 2004; 52:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/39\">",
"      Morris PL, Robinson RG, Andrzejewski P, et al. Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993; 150:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/40\">",
"      Rovner BW, German PS, Brant LJ, et al. Depression and mortality in nursing homes. JAMA 1991; 265:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/41\">",
"      von Ammon Cavanaugh S, Furlanetto LM, Creech SD, Powell LH. Medical illness, past depression, and present depression: a predictive triad for in-hospital mortality. Am J Psychiatry 2001; 158:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/42\">",
"      Gallo JJ, Bogner HR, Morales KH, et al. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. Ann Intern Med 2007; 146:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/43\">",
"      Blow FC, Brockmann LM, Barry KL. Role of alcohol in late-life suicide. Alcohol Clin Exp Res 2004; 28:48S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/44\">",
"      Beekman AT, de Beurs E, van Balkom AJ, et al. Anxiety and depression in later life: Co-occurrence and communality of risk factors. Am J Psychiatry 2000; 157:89.",
"     </a>",
"    </li>",
"    <li>",
"     Hoyert, DL, Kochanek, KD, Murphy, SL. Deaths: Final data for 1997. National Vital Statistics Reports 1999: 47:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/46\">",
"      Waern M, Runeson BS, Allebeck P, et al. Mental disorder in elderly suicides: a case-control study. Am J Psychiatry 2002; 159:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Homicides and suicides--National Violent Death Reporting System, United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006; 55:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/48\">",
"      Szanto K, Mulsant BH, Houck P, et al. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003; 60:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/49\">",
"      Alexopoulos GS, Bruce ML, Hull J, et al. Clinical determinants of suicidal ideation and behavior in geriatric depression. Arch Gen Psychiatry 1999; 56:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/50\">",
"      Bruce ML, Ten Have TR, Reynolds CF 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA 2004; 291:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/51\">",
"      Kales HC, Maixner DF, Mellow AM. Cerebrovascular disease and late-life depression. Am J Geriatr Psychiatry 2005; 13:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/52\">",
"      Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002; 53:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/53\">",
"      Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry 1997; 54:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/54\">",
"      Kumar A, Jin Z, Bilker W, et al. Late-onset minor and major depression: early evidence for common neuroanatomical substrates detected by using MRI. Proc Natl Acad Sci U S A 1998; 95:7654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/55\">",
"      Sheline YI, Price JL, Vaishnavi SN, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry 2008; 165:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/56\">",
"      Thomas AJ, Kalaria RN, O'Brien JT. Depression and vascular disease: what is the relationship? J Affect Disord 2004; 79:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/57\">",
"      Tupler LA, Krishnan KR, McDonald WM, et al. Anatomic location and laterality of MRI signal hyperintensities in late-life depression. J Psychosom Res 2002; 53:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/58\">",
"      Kumar A, Thomas A, Lavretsky H, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry 2002; 159:630.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/60\">",
"      Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/61\">",
"      Wilson RS, Barnes LL, Mendes de Leon CF, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002; 59:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/62\">",
"      Modrego PJ, Ferr&aacute;ndez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004; 61:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/63\">",
"      Berger AK, Fratiglioni L, Forsell Y, et al. The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology 1999; 53:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/64\">",
"      Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 2003; 60:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/65\">",
"      Butters MA, Whyte EM, Nebes RD, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry 2004; 61:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/66\">",
"      Devanand DP, Adorno E, Cheng J, et al. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord 2004; 78:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/67\">",
"      Lavretsky H, Kumar A. Clinically significant non-major depression: old concepts, new insights. Am J Geriatr Psychiatry 2002; 10:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/68\">",
"      Williams JW Jr, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. JAMA 2000; 284:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/69\">",
"      Penninx BW, Geerlings SW, Deeg DJ, et al. Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry 1999; 56:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/70\">",
"      Lyness JM, Heo M, Datto CJ, et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Intern Med 2006; 144:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/71\">",
"      Per&auml;l&auml; J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/72\">",
"      Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 2002; 159:1855.",
"     </a>",
"    </li>",
"    <li>",
"     Blazer D. Epidemiology of late-life depression. In: Schneider L, Reynolds C, Lebowitz B, Friedhoff A Eds, Diagnosis and Treatment of Depression in Late Life. American Psychiatric Press, Washington, DC 1994. p.9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/74\">",
"      Kivel&auml; SL, Pahkala K. Delusional depression in the elderly: a community study. Z Gerontol 1989; 22:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/75\">",
"      Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003; 54:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/76\">",
"      Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry 1997; 154:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/77\">",
"      Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry 2004; 55:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/78\">",
"      Steffens DC, Taylor WD, Krishnan KR. Progression of subcortical ischemic disease from vascular depression to vascular dementia. Am J Psychiatry 2003; 160:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/79\">",
"      van der Wurff FB, Stek ML, Hoogendijk WJ, Beekman AT. The efficacy and safety of ECT in depressed older adults: a literature review. Int J Geriatr Psychiatry 2003; 18:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/80\">",
"      Alexopoulos GS. \"The depression-executive dysfunction syndrome of late life\": a specific target for D3 agonists? Am J Geriatr Psychiatry 2001; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/81\">",
"      Vataja R, Pohjasvaara T, M&auml;ntyl&auml; R, et al. Depression-executive dysfunction syndrome in stroke patients. Am J Geriatr Psychiatry 2005; 13:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/82\">",
"      Alexopoulos GS, Kiosses DN, Klimstra S, et al. Clinical presentation of the \"depression-executive dysfunction syndrome\" of late life. Am J Geriatr Psychiatry 2002; 10:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/83\">",
"      Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002; 52:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/84\">",
"      Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/85\">",
"      Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/86\">",
"      Sirey JA, Bruce ML, Alexopoulos GS, et al. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry 2001; 158:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/87\">",
"      L&ouml;we B, Spitzer RL, Gr&auml;fe K, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians' diagnoses. J Affect Disord 2004; 78:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/88\">",
"      Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/89\">",
"      Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 2003; 327:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/90\">",
"      Li C, Friedman B, Conwell Y, Fiscella K. Validity of the Patient Health Questionnaire 2 (PHQ-2) in identifying major depression in older people. J Am Geriatr Soc 2007; 55:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/91\">",
"      Montorio I, Izal M. The Geriatric Depression Scale: a review of its development and utility. Int Psychogeriatr 1996; 8:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/92\">",
"      Rinaldi P, Mecocci P, Benedetti C, et al. Validation of the five-item geriatric depression scale in elderly subjects in three different settings. J Am Geriatr Soc 2003; 51:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/93\">",
"      Hoyl MT, Alessi CA, Harker JO, et al. Development and testing of a five-item version of the Geriatric Depression Scale. J Am Geriatr Soc 1999; 47:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/94\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/95\">",
"      L&ouml;we B, Un&uuml;tzer J, Callahan CM, et al. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 2004; 42:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/96\">",
"      Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/97\">",
"      Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health 1993; 5:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/98\">",
"      Radloff, LS. The CES-D scale: the self-reported depression scale for research in the general population. Appl Psychol Meas 1977; 1:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/99\">",
"      Thielke SM, Fan MY, Sullivan M, Un&uuml;tzer J. Pain limits the effectiveness of collaborative care for depression. Am J Geriatr Psychiatry 2007; 15:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/100\">",
"      Beekman AT, Deeg DJ, van Tilburg T, et al. Major and minor depression in later life: a study of prevalence and risk factors. J Affect Disord 1995; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/101\">",
"      Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 2006; 163:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/102\">",
"      Are&aacute;n PA, Cook BL. Psychotherapy and combined psychotherapy/pharmacotherapy for late life depression. Biol Psychiatry 2002; 52:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/103\">",
"      Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/104\">",
"      Un&uuml;tzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002; 288:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/105\">",
"      Hegel, MT, Imming, J, Cyr-Provost, MA, et al. Role of behavioral health professionals in a collaborative stepped care treatment model for depression in primary care: Project IMPACT. Family Systems Health 2002; 20:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/106\">",
"      Katon WJ, Schoenbaum M, Fan MY, et al. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry 2005; 62:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/107\">",
"      Hunkeler EM, Katon W, Tang L, et al. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. BMJ 2006; 332:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/108\">",
"      Un&uuml;tzer J, Tang L, Oishi S, et al. Reducing suicidal ideation in depressed older primary care patients. J Am Geriatr Soc 2006; 54:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/109\">",
"      Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 2011; 72:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/110\">",
"      Sj&ouml;sten N, Kivel&auml; SL. The effects of physical exercise on depressive symptoms among the aged: a systematic review. Int J Geriatr Psychiatry 2006; 21:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/111\">",
"      Morgan AC. Practical geriatrics: psychodynamic psychotherapy with older adults. Psychiatr Serv 2003; 54:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/112\">",
"      Reynolds CF 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/113\">",
"      Haverkamp R, Are&aacute;n P, Hegel MT, Un&uuml;tzer J. Problem-solving treatment for complicated depression in late life: a case study in primary care. Perspect Psychiatr Care 2004; 40:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/114\">",
"      Ciechanowski P, Wagner E, Schmaling K, et al. Community-integrated home-based depression treatment in older adults: a randomized controlled trial. JAMA 2004; 291:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/115\">",
"      Miller MD, Frank E, Cornes C, et al. The value of maintenance interpersonal psychotherapy (IPT) in older adults with different IPT foci. Am J Geriatr Psychiatry 2003; 11:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/116\">",
"      Wilson KC, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older depressed people. Cochrane Database Syst Rev 2008; :CD004853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/117\">",
"      Gould RL, Coulson MC, Howard RJ. Cognitive behavioral therapy for depression in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc 2012; 60:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/118\">",
"      Are&aacute;n PA, Raue P, Mackin RS, et al. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. Am J Psychiatry 2010; 167:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/119\">",
"      Alexopoulos GS, Raue PJ, Kiosses DN, et al. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction: effect on disability. Arch Gen Psychiatry 2011; 68:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/120\">",
"      Guerriero Austrom M, Damush TM, Hartwell CW, et al. Development and implementation of nonpharmacologic protocols for the management of patients with Alzheimer's disease and their families in a multiracial primary care setting. Gerontologist 2004; 44:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/121\">",
"      Mittelman MS, Roth DL, Coon DW, Haley WE. Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease. Am J Psychiatry 2004; 161:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/122\">",
"      Stanley MA, Wilson NL, Novy DM, et al. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA 2009; 301:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/123\">",
"      Givens JL, Datto CJ, Ruckdeschel K, et al. Older patients' aversion to antidepressants. A qualitative study. J Gen Intern Med 2006; 21:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/124\">",
"      Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; :CD003491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/125\">",
"      Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/126\">",
"      Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004; 19:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/127\">",
"      Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001; 18:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/128\">",
"      Mittmann N, Herrmann N, Shulman KI, et al. The effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study. J Clin Psychiatry 1999; 60:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/129\">",
"      Mulsant BH, Houck PR, Gildengers AG, et al. What is the optimal duration of a short-term antidepressant trial when treating geriatric depression? J Clin Psychopharmacol 2006; 26:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/130\">",
"      Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry 2007; 164:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/131\">",
"      Bao Y, Post EP, Ten TR, et al. Achieving effective antidepressant pharmacotherapy in primary care: the role of depression care management in treating late-life depression. J Am Geriatr Soc 2009; 57:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/132\">",
"      Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. Am J Psychiatry 2005; 162:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/133\">",
"      Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev 2012; 11:CD006727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/134\">",
"      Reynolds CF 3rd, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/135\">",
"      Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med 2004; 164:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/136\">",
"      Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/137\">",
"      Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006; 163:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/138\">",
"      Kuehn BM. FDA panel seeks to balance risks in warnings for antidepressants. JAMA 2007; 297:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/139\">",
"      Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 1998; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). file://www.fda.gov/Drugs/DrugSafety/ucm269086.htm (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses file://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/142\">",
"      Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/143\">",
"      Oslin DW, Ten Have TR, Streim JE, et al. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003; 64:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/144\">",
"      Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997; 33:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/145\">",
"      Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/146\">",
"      Gnanadesigan N, Espinoza RT, Smith R, et al. Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected? J Am Med Dir Assoc 2005; 6:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/147\">",
"      Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/148\">",
"      Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/149\">",
"      Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry 2001; 16:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/150\">",
"      Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009; 5:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/151\">",
"      Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/152\">",
"      Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/153\">",
"      Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients With Major Depressive Disorder. Am J Geriatr Psychiatry 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/154\">",
"      Brodaty H, Hickie I, Mason C, Prenter L. A prospective follow-up study of ECT outcome in older depressed patients. J Affect Disord 2000; 60:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/155\">",
"      Tew JD Jr, Mulsant BH, Haskett RF, et al. Acute efficacy of ECT in the treatment of major depression in the old-old. Am J Psychiatry 1999; 156:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/156\">",
"      Husain MM, Rush AJ, Fink M, et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004; 65:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/157\">",
"      O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. Report. Am J Geriatr Psychiatry 2001; 9:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/158\">",
"      Frazer, CJ, Christensen, H, Griffiths, KM. Effectiveness of treatments for depression in older people, Med J Aust 2005; 182:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/159\">",
"      Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil 2009; 23:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/160\">",
"      Penninx, BWJH, Rejeski, WJ, Pandya, J, et al. Exercise and depressive symptoms: a comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. J Gerontol B Psychol Sci Soc Sci 2002; 57:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/161\">",
"      Lieverse R, Van Someren EJ, Nielen MM, et al. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry 2011; 68:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/162\">",
"      Un&uuml;tzer J, Park M. Older adults with severe, treatment-resistant depression. JAMA 2012; 308:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/163\">",
"      Jeong H, Yim HW, Jo SJ, et al. The effects of care management on depression treatment in a psychiatric clinic: a randomized controlled trial. Int J Geriatr Psychiatry 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/37/39514/abstract/164\">",
"      Reynolds CF 3rd, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011; 68:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1719 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39514=[""].join("\n");
var outline_f38_37_39514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Nursing home residence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Gender differences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Physical illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Impact",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Medical comorbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Psychiatric comorbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Suicide risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dysthymia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Subsyndromal depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psychotic depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vascular depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alzheimer disease and other dementias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Depression diagnosis with medical comorbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Depression diagnosis in the frail elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Screening instruments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Treatment for anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Medication acceptance by patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Medication selection and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Antidepressant medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Selective serotonin reuptake inhibitors (SSRIs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Serotonin-norepinephrine reuptake inhibitors (SNRIs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Atypical antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Tricyclic and tetracyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Monoamine oxidase inhibitors (MAOIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2540898\">",
"      Quetiapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21628528\">",
"      Neurostimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Other brain stimulation therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3262160\">",
"      Bright light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3262263\">",
"      Collaborative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3262478\">",
"      Family support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88015669\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1719|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/31/26110\" title=\"figure 1\">",
"      Depression prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1719|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/1/22556\" title=\"table 2\">",
"      Depression in AD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/16/42251\" title=\"table 3\">",
"      Screening tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/12/14541\" title=\"table 4\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/12/37070\" title=\"table 5\">",
"      Antidepressants in older adults and medically ill",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/53/33627\" title=\"table 6\">",
"      Drug properties MAOIs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/38/18025?source=related_link\">",
"      Family and couples therapy for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17674?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/39/9850?source=related_link\">",
"      Unipolar depression in adults: Continuation and maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/30/6633?source=related_link\">",
"      Unipolar depression in adults: Overview of neuromodulation procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31993?source=related_link\">",
"      Unipolar depression in adults: Treatment with second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5097?source=related_link\">",
"      Unipolar depression in adults: Treatment with surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16682?source=related_link\">",
"      Unipolar depression in adults: Treatment with transcranial magnetic stimulation (TMS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4105?source=related_link\">",
"      Unipolar major depression with psychotic features: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5368?source=related_link\">",
"      Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=related_link\">",
"      Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_37_39515="Disability criteria per PFT";
var content_f38_37_39515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Social security disability criteria based on pulmonary function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Height without shoes (in)",
"       </td>",
"       <td class=\"subtitle1\">",
"        FEV1 equal to or less than (L,",
"BTPS**)",
"       </td>",
"       <td class=\"subtitle1\">",
"        MVV equal to or less than",
"(L/min, BTPS)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vital capacity equal to or",
"less than (L, BTPS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 or less",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        61 to 63",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        64 to 65",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66 to 67",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        68 to 69",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70 to 71",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        72 or more",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Adjusted for body temperature, pressure, and saturation.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Disability Evaluation under Social Security. US Department of Health and Human Services, SSA Publication No. 05-10089, February 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39515=[""].join("\n");
var outline_f38_37_39515=null;
var title_f38_37_39516="AML Risk Stratification European LeukemiaNet 2010";
var content_f38_37_39516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Standardized reporting for correlation of cytogenetic and molecular genetic data in acute myeloid leukemia with clinical data",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Genetic group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subsets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Favorable",
"       </td>",
"       <td>",
"        t(8;21)(q22;q22);",
"        <em>",
"         RUNX1-RUNX1T1",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        inv(16)(p13.1q22) or t(16;16)(p13.1;q22);",
"        <em>",
"         CBFB-MYH11",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutated",
"        <em>",
"         NPM1",
"        </em>",
"        without",
"        <em>",
"         FLT3",
"        </em>",
"        -ITD (normal karyotype)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutated",
"        <em>",
"         CEBPA",
"        </em>",
"        (normal karyotype)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Intermediate-I*",
"       </td>",
"       <td>",
"        Mutated",
"        <em>",
"         NPM1",
"        </em>",
"        and",
"        <em>",
"         FLT3",
"        </em>",
"        -ITD (normal karyotype)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wild-type",
"        <em>",
"         NPM1",
"        </em>",
"        and",
"        <em>",
"         FLT3",
"        </em>",
"        -ITD (normal karyotype)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wild-type",
"        <em>",
"         NPM1",
"        </em>",
"        without",
"        <em>",
"         FLT3",
"        </em>",
"        -ITD (normal karyotype)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Intermediate-II",
"       </td>",
"       <td>",
"        t(9;11)(p22;q23);",
"        <em>",
"         MLLT3-MLL",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytogenetic abnormalities not classified as favorable or adverse&bull;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Adverse",
"       </td>",
"       <td>",
"        inv(3)(q21q26.2) or t(3;3)(q21;q26.2);",
"        <em>",
"         RPN1-EVI1",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        t(6;9)(p23;q34);",
"        <em>",
"         DEK-NUP214",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        t(v;11)(v;q23);",
"        <em>",
"         MLL",
"        </em>",
"        rearranged",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -5 or del(5q); -7; abnl(17p); complex karyotype&Delta;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Frequencies, response rates, and outcome measures should be reported by genetic group, and, if sufficient numbers are available, by specific subsets indicated; excluding cases of acute promyelocytic leukemia.",
"    <div class=\"footnotes\">",
"     AML: acute myeloid leukemia; WHO: World Health Organization.",
"     <br>",
"      * Includes all AMLs with normal karyotype except for those included in the favorable subgroup.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       For most abnormalities, adequate numbers have not been studied to draw firm conclusions regarding their prognostic significance.",
"       <br>",
"        &Delta; Three or more chromosome abnormalities in the absence of one of the WHO designated recurring translocations or inversions, that is, t(15;17), t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23), t(6;9), inv(3) or t(3;3).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. D&ouml;hner, H, Estey, EH, Amadori, S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453. Copyright &copy; 2010 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39516=[""].join("\n");
var outline_f38_37_39516=null;
var title_f38_37_39517="CMT types 1 through 3";
var content_f38_37_39517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetics of CMT1, CTM2, and CMT3",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        CMT1",
"       </td>",
"       <td>",
"        Onset in first or second decade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1A",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Motor symptoms predominate (clumsy walking)",
"        </p>",
"        <p>",
"         Gradual loss of proprioception and vibration",
"        </p>",
"        <p>",
"         Ambulation usually maintained",
"        </p>",
"        <p>",
"         Normal life expectancy",
"        </p>",
"        <p>",
"         Palpable enlargement of the peripheral nerves",
"        </p>",
"        <p>",
"         NCV slowed to &lt;60 percent normal",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1B",
"       </td>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1C",
"       </td>",
"       <td>",
"        LITAF",
"       </td>",
"       <td>",
"        16p.13.1-p12.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1D",
"       </td>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-q22.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1E",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT1F",
"       </td>",
"       <td>",
"        NEFL",
"       </td>",
"       <td>",
"        8p21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Roussy-Levy",
"       </td>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         CTM1 features plus:",
"        </p>",
"        <p>",
"         Postural tremor and gait ataxia",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMTX1",
"       </td>",
"       <td>",
"        GJB1",
"       </td>",
"       <td>",
"        Xq13.1",
"       </td>",
"       <td>",
"        <p>",
"         CMT1 features plus:",
"        </p>",
"        <p>",
"         Symptoms more prominent in males",
"        </p>",
"        <p>",
"         Symptomatic in second decade",
"        </p>",
"        <p>",
"         Loss of ankle reflexes",
"        </p>",
"        <p>",
"         NCV moderately slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        CMT2",
"       </td>",
"       <td>",
"        Onset in second or third decade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CTM2A",
"       </td>",
"       <td>",
"        MFN2",
"       </td>",
"       <td>",
"        1p36.2",
"       </td>",
"       <td rowspan=\"10\">",
"        Sensory symptoms predominate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CTM2B",
"       </td>",
"       <td>",
"        RAB7",
"       </td>",
"       <td>",
"        3q21.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2C",
"       </td>",
"       <td>",
"        TRPV4",
"       </td>",
"       <td>",
"        12q24.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CTM2D",
"       </td>",
"       <td>",
"        GARS",
"       </td>",
"       <td>",
"        7p15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2E",
"       </td>",
"       <td>",
"        NEFL",
"       </td>",
"       <td>",
"        8p",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2F",
"       </td>",
"       <td>",
"        HSPB1",
"       </td>",
"       <td>",
"        7q11.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2G",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        12q12-q13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2I",
"       </td>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2K",
"       </td>",
"       <td>",
"        GDAP1",
"       </td>",
"       <td>",
"        8q13-q21.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT2L",
"       </td>",
"       <td>",
"        HSPB8",
"       </td>",
"       <td>",
"        12q24.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Early onset",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Not known",
"       </td>",
"       <td>",
"        <p>",
"         Onset before age 5 years",
"        </p>",
"        <p>",
"         Rapid progression of weakness below the knee",
"        </p>",
"        <p>",
"         Loss of ambulation by mid-teens",
"        </p>",
"        <p>",
"         NCV normal or mildly reduced",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        CMT3",
"       </td>",
"       <td>",
"        Severe, early onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Dejerine-Sottas syndrome",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Hypotonia in early infancy",
"        </p>",
"        <p>",
"         Delayed motor development",
"        </p>",
"        <p>",
"         Initial sensory loss and distal weakness",
"        </p>",
"        <p>",
"         Ataxia",
"        </p>",
"        <p>",
"         NCV profoundly slowed (10m/sec)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-q22.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Congenital hypomyelinating neuropathy",
"       </td>",
"       <td>",
"        PMP22",
"       </td>",
"       <td>",
"        17p11.2-p1",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Profound hypotonia and contractures at birth",
"        </p>",
"        <p>",
"         Feeding difficulties",
"        </p>",
"        <p>",
"         Respiratory distress",
"        </p>",
"        <p>",
"         Death in infancy",
"        </p>",
"        <p>",
"         NCV extremely slowed or absent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MPZ",
"       </td>",
"       <td>",
"        1q22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-q22.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39517=[""].join("\n");
var outline_f38_37_39517=null;
var title_f38_37_39518="Approach to prevention in adolescents";
var content_f38_37_39518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Approach to organizing the preventive health evaluation of the adolescent patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 529px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39518=[""].join("\n");
var outline_f38_37_39518=null;
var title_f38_37_39519="Gastric band adjustment";
var content_f38_37_39519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric band adjustment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The gastric band consists of a soft, locking silicone ring connected to an infusion port placed in the subcutaneous tissue. The port may be accessed with relative ease by a syringe and needle. Injection of saline into the port leads to reduction in the band diameter, resulting in an increased degree of restriction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_37_39519=[""].join("\n");
var outline_f38_37_39519=null;
